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ABSTRACT 
Human mesenchymal stem/stromal cells (hMSCs) are currently used in 
many advanced cellular therapies. The clinical use of hMSCs requires 
extensive cell expansion, but the consequences of expansion, especially at the 
molecular level, are not fully understood. The therapeutic effect of MSCs is 
mediated at least partially via paracrine interactions with immune cells 
modulating both innate and adaptive immune response. Membrane 
glycerophospholipids (GPLs) provide precursors for signaling lipids, which 
modulate cellular functions, including immunological effects via eicosanoids 
and docosanoids. 
The aim of this study was to investigate the effect of the donor’s age and 
cell doublings on the GPLs, gene expression and microRNA (miRNA) profiles 
of human bone marrow MSCs (hBM-MSC). In order to gain more insight into 
the functional mechanisms of MSCs, we investigated the extracellular vesicle 
(EV) secretion from human umbilical cord blood derived MSCs (hCB-MSC), 
and evaluated their immunosuppressive capacity in vitro as well as their 
possible immunomodulative and protective effect in kidney ischemia-
reperfusion injury (IRI) in vivo. We were able to demonstrate that the hBM-
MSCs, harvested from 5 young adults and 5 old donors, showed clear 
compositional changes in their GPL profiles during expansion. Most 
strikingly, the molar ratio of prostaglandin E2 precursor arachidonic acid 
(20:4n-6) containing species of phosphatidylcholine and 
phosphatidylethanolamine accumulated, while the species containing 
monounsaturated fatty acids decreased during passaging. The lipid changes 
correlated with the decreased immunosuppressive capacity of hBM-MSCs 
during expansion, suggesting a connection between lipid signaling and 
immunomodulatory functions. The existence of such a connection was 
further supported by gene expression results for several enzymes involved in 
lipid metabolism and immunomodulation. Our results show that extensive 
expansion of hBM-MSCs harmfully modulates membrane GPLs, affecting 
lipid signaling, and eventually impairing functionality. 
Although we were able to see clear alterations in gene expression levels 
and lipid profiles, the miRNA expression was more stable. To summarize, the 
expression levels of 37 miRNAs were changed in the old donors group and 36 
miRNAs were changed in the young donors group. Of these, only 12 were 
differentially expressed in both young and old donor BM-MSCs and their 
predicted target mRNAs, the expression of which was changed, were mainly 
linked to cell proliferation and senescence. Interestingly, members of the 
well-studied miR-17/92 cluster, which is involved in cell cycle regulation, 
aging and the development of immune system, were down-regulated 
especially in the old donors group. The role of this cluster in MSC 
 functionality is worth future studies since it links expansion, aging and 
immune system together. 
When we studied the immunological effect of EVs derived from CB-MSC, 
we were able to demonstrate their immunological potential both in vitro and 
in vivo. Interestingly, these properties were weakened especially in the 
animal model when MSCs were preconditioned with interferon gamma. A 
comparative mass spectrometric analysis revealed a clear distinction in the 
protein content of the IFNγ stimulated EVs. We discovered that two 
differently produced EV pools contained specific Rab proteins suggesting 
that, depending on external signals, the same cells produce vesicles 
originating from different intracellular locations, which also influences their 
functional properties. 
In conclusion, these studies provide a detailed analysis of molecular 
changes during MSC expansion. The present study demonstrates that the 
combination of in vitro and in vivo models accompanied with a detailed 
analysis of molecular characteristics is essential to a profound understanding 
of the complexity of the MSC paracrine regulation. 
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1 INTRODUCTION 
Mesenchymal stem/stromal cells (MSCs) were first described as non-
hematopoietic progenitor cells from the bone marrow in the 1960’s by 
Friedenstein and co-workers (Friedenstein et al. 1968). Traditionally 
minimal criteria of International Society for Cellular Therapies (ISCT) 
defines MSCs as plastic adherent fibroblast like cells that are capable of 
differentiating into adipocytes, osteoblasts and chondrocytes and that 
express certain cell surface markers (CD73,CD90 and CD105) but not 
hematopoietic markers (CD14, CD19, CD34, CD45,  and HLA-DR)  (Dominici 
et al. 2006). One of the most fascinating properties of MSCs is their versatile 
ability to modulate immune cells and enhance the repair of injured tissue. 
The immunomodulative capacity has made MSCs one of the most attractive 
cell types for advanced cellular therapies and therefore ISCT suggests that an 
immunosuppression assay should be included in the releasing criteria for a 
clinical-grade MSC product (Galipeau et al. 2016). 
After the initial discovery in the bone marrow, MSCs have been isolated 
from several other adult and fetal tissues. It has been suggested that MSCs 
reside inside all tissues nearby perivascular space (da Silva Meirelles et al. 
2008). However, the identification of MSCs’ in vivo location and 
physiological role has been extremely challenging, and little is known about 
their true identity and role in the tissue homeostasis. Several molecular 
mechanisms have been described, but many open questions still remain. 
How do these cells perform their function and how many different types of 
MSCs are there in the body? 
After establishment, MSCs are expanded in vitro. MSCs, like other 
primary cells, are not able to divide infinitely, but reach cellular senescence.  
In recent years, the use of autologous MSCs in several indications impacting 
aged patients has increased. Donor age introduces another dimension to the 
puzzle of MSC therapy. The effects of donor age and extensive expansion on 
the characteristics and functionality of hBM-MSCs are worth studying, in 
order to develop more efficient MSC therapies. 
Review of the literature 
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2 REVIEW OF THE LITERATURE 
2.1 Mesenchymal stromal cell niche 
Niches are local tissue microenvironments that maintain and regulate stem 
cells. Hematopoietic stem cell (HSC) niches are present in diverse tissues 
throughout the development, beginning with the yolk sac, followed by 
placenta, fetal liver and finally bone marrow (Mikkola and Orkin 2006). In 
the adult human body, bone marrow has many crucial functions. Most 
importantly bone marrow is the scene of hematopoiesis, a process that leads 
to formation of all blood cells. Hematopoietic stem cells (HSC) are self-
renewing and multipotent cells giving rise to all blood cells of the myeloid 
and lymphoid lineages (Figure 1). The HSC pool comprises actively self-
renewing HSCs (ST-HSC) and quiescent long-term HSCs (LT-HSC). The 
bone marrow microenvironment seems to be adapted to support these HSC 
properties. Using mouse as the animal model, it has been suggested that 
these two types of HSCs are located in different places: LT-HSCs near the 
endosteum (endosteal niche) and ST-HSC in connection with sinusoidal 
endothelium (perivascular niche) (Wilson et al. 2008). HSCs are located in 
the bone marrow in accordance with their differentiation state, and it is the 
blood flow rate rather than the actual distance from the endosteum that 
defines the niche (Winkler et al. 2010a). The development of more specific 
labels to identify HSCs in vivo has shown that most of the HSCs are found 
near sinusoids in the highly vascular endosteal region (Nombela-Arrieta et 
al. 2013). 
In addition to HSCs, a heterogeneous population of stromal cells is found 
in the bone marrow. A small proportion of these MSCs exhibit stem cell 
characteristics, such as self-renewing capacity and differentiation potential 
into adipocytes, osteoblasts and chondrocytes (Figure 1). The identification 
of MSCs in vivo is challenging and therefore MSCs are defined according to 
their characteristics in vitro.  In mice, several mesenchymal progenitors, 
such as CXC chemokine ligand (CXCL) 12 abundant reticular (CAR) cells 
(Omatsu et al. 2010, Sugiyama et al. 2006), stem cell factor expressing cells 
(Ding et al. 2012), nestin expressing cells (Mendez-Ferrer et al. 2010) and 
platelet derived growth factor receptor a (PDGFR-a)+, Sca-1+, CD45- and 
Ter119- cells (Ding and Morrison 2013, Greenbaum et al. 2013), have been 
described. All these cells possess highly similar properties, indicating that 
bone marrow may contain several different pools of MSCs with different 
roles in the regulation of HSCs. In human bone marrow, CD146+ 
osteoprogenitors with self-renewing capacity have been described, indicating 
that stromal cells are necessary for maintaining HSC niche also in the human 
bone marrow (Sacchetti et al. 2007).  
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Figure 1 The regenerative cells of the bone marrow niche. A. Hematopoietic stem cells 
(HSC) are precursors of all mature blood cells. A proportion of these self-renewing cells remain 
undifferentiated to maintain a pool of long-term reconstituting HSCs (LT-HSC) and short term 
reconstituting HSCs (ST-HSC). B. Bone marrow mesenchymal stromal cells (BM-MSCs) are 
multipotent, self-renewing progenitor cells that can differentiate into other cell types.?
Abbreviations: CLP, common lymphoid progenitor cell; CMP, common myeloid progenitor; MPP, 
multipotent progenitor; NK cell, natural killer cell. Adapted by permission from Macmillan 
Publishers Ltd: Nature Reviews Rheumatology 12:154:168, copyright 2015. 
Recent advances in imaging techniques have elucidated the location and 
role of MSCs in the microenvironment of bone marrow. Similar findings in 
fetal human bone marrow are available, (Pinho et al. 2013) but a more 
detailed analysis of the HSC niche in humans is required. According to the 
animal studies, MSCs reside mostly perivascularly together with HSCs, but 
traffic to the endosteal surface to differentiate into osteoblasts (Morrison and 
Scadden 2014). Recently, a new pool of progenitor cells was described and 
called bone lining cells. These cells are located on the endosteal surface and 
act as precursors for osteoblasts and osteoclasts (Matic et al. 2016). The 
adipogenic potential of these cells has yet to be investigated, but these results 
reinforce the possibility of secondary pool of MSCs in the bone marrow. One 
of the major tasks of MSCs is to create a supportive microenvironment for 
HSCs self-renewal and quiescence in the bone marrow (Mendez-Ferrer et al. 
2010, Omatsu et al. 2010). MSCs produce stem cell factor (SCF) and stromal 
derived factor (SDF1,) also called CXCL12, and other cytokines that promote 
the maintenance of HSCs (Sacchetti et al. 2007). In addition to the soluble 
molecules, miRNAs, delivered in extracellular vesicles, may act as one 
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mechanism for the maintenance of HSCs (De Luca et al. 2016). The 
interaction between MSCs and HSCs is far more complex and studies have 
shown that also HSCs secrete cytokines relevant to the proliferation and 
differentiation of MSCs as well as to the inhibition of their senescence (Zhou 
2015).  
Besides HSCs and MSCs, there are several other cell types residing in the 
niche that are essential for its function. These include osteoblasts, osteoclasts 
endothelial cells, bone marrow adipocytes, megakaryocytes, tissue resident 
macrophages, immune cells, and neurons (Figure 2). Osteoblasts were the 
first cell population shown to have an influence on HSCs. Two groups 
showed with animal models that osteolineage cell activation increased HSC 
number in vivo (Calvi et al. 2003, Zhang et al. 2003). The interaction of 
angiopoietin-1, expressed by osteoblasts, with its receptor Tie-2, expressed 
by HSCs, is shown to be essential for HSC quiescence (Arai et al. 2004). Also, 
local calcium ion concentration has been shown to recruit HSCs to 
endosteum via calcium sensing receptors (Adams et al. 2006). Osteoclasts 
are derived from the HSCs in the bone marrow. There is evidence that in 
addition to participating in the remodeling of the bone, osteoclasts also 
regulate the HSC niche through the degradation of CXCL12 and SCF (Kollet 
et al. 2006). Currently, the roles of endosteum, as a regulatory region, and 
osteoprogenitor cells in the maintenance of HSCs are acknowledged, but 
mature osteoblasts and osteoclast contribute to the HSC maintenance most 
likely indirectly through the modulation of the microenvironment (Morrison 
and Scadden 2014). 
Figure 2 Structure and cellular components of bone marrow niche. Bone marrow is a 
complex organ containing hematopoietic and non-hematopoietic cell types. The interface of bone 
marrow is called endosteum, which is covered by bone lining cells, osteoblasts and osteoclasts. 
Sinusoids are specialized blood vessels that allow trafficking of cells into circulation. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology 12:154-168, copyright 
2015. 
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Sinusoidal endothelial cells participate in the maintenance of HSCs by 
expressing SDF-1 (Greenbaum et al. 2013), SCF (Ding et al. 2012) vascular 
endothelial growth factor (VEGF) receptor 2 (Hooper et al. 2009) and e-
selectin (Winkler et al. 2012). Megakaryocytes contribute to the niche by 
supporting HSC quiescence through the production of CXCL4 and 
transforming growth factor (TGF)-β (Bruns et al. 2014, Zhao et al. 2014b). 
Marrow adipocytes residing near the endosteal surface do not only act as a 
filler in the bone marrow, but are also necessary for the maintenance of HSC 
quiescence through endocrine and paracrine effects (Naveiras et al. 2009). 
Bone marrow resident macrophages are distributed throughout the bone 
marrow and are necessary for the endosteal bone marrow niche. 
Macrophages regulate HSC dormancy by keeping them in their stem-cell 
state while supporting bone formation via the regulation of MSC osteogenic 
differentiation (Chang et al. 2008, Winkler et al. 2010b). Finally, the 
sympathetic nervous system regulates CXCL12-expression in the bone 
marrow and further HSC mobilization to the circulation (Katayama et al. 
2006). HSC mobilization follows physiologically regulated circadian 
rhythms. Cyclic release of HSCs and downregulation of CXCL12 are regulated 
by molecular clock genes mediated by circadian release of noradrenaline 
from sympathetic nerves. The signal is mediated through β3 adrenoreceptor 
that is expressed by MSCs (Mendez-Ferrer et al. 2008). 
If the bone marrow is the scene of hematopoiesis in the adult human 
body, placenta is a unique hematopoietic organ during the development 
(Gekas et al. 2005). In contrast to the bone marrow, HSCs are not 
maintained in dormancy during the development but expand actively 
without differentiation. HSCs are formed in the large vessels of 
chorionallantoic mesenchyme and expand in the placental vascular 
labyrinth. In humans, HSCs seems to be present in the placenta throughout 
the development. Similar to the bone marrow, the placenta contains stromal 
cells that support HSCs in vitro (Robin et al. 2009). In the human placenta, 
MSCs are located particularly in the chorionic villi of the placenta residing 
near blood vessels and regulate vessel maturation and stabilization 
(Castrechini et al. 2010). The regulation of the HSC niche is complex and 
involves the activity of several cell types including MSCs, trophoblasts and 
endothelial cells. One of the key mechanisms for regulating HSCs in the 
placenta is PDGF-B signaling (Chhabra et al. 2012). Compared to the bone 
marrow, cellular components and molecular signals maintaining the 
microenvironment in the placenta are not well understood.  
Review of the literature 
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2.2 Mesenchymal stromal cells in cell therapy 
MSCs have several properties that make them an intriguing tool for cellular 
therapy. They have been considered immune privileged since they express 
low levels of major histocompatibility complex class 1 (MHCI) and they do 
not constitutively express MHC class II or costimulatory molecules such as 
CD40, CD80, and CD86 (Tse et al. 2003). These features could protect them 
from alloreactive natural killer (NK) cell lysis and promote their survival and 
growth in an allogenic environment (Sotiropoulou et al. 2006). Later studies 
have shown that MSCs are rejected by NK cells and therefore they should be 
considered immune evasive rather than immune privileged (Ankrum et al. 
2014). MSCs have the ability to home to the sites of inflammation (Spaeth et 
al. 2008) and perform immunomodulatory functions in the injured tissue. 
MSCs use both direct cell-to-cell contact as well secreted soluble 
immunosuppressive molecules to interact with a wide range of immune cells, 
including T cells, B cells, NK cells, dendritic cells, and macrophages. 
Although MSCs are able to differentiate into various cell types, many of 
their favorable effects are mediated through cell-to-cell communication, 
which inhibits inflammation and stimulates the recovery of injured tissue 
(Figure 3). MSCs communicate with target cells either via paracrine 
signaling or direct cell-to cell contact. In addition to soluble molecules like 
bioactive lipids, growth factors and cytokines, paracrine mechanisms of 
MSCs include secreted extracellular vesicles (EVs). EVs encompass different 
types of vesicles that differ by their route of origin. Shedding vesicles or 
microvesicles are produced by outward budding and fission of plasma 
membrane. Exosomes originate inside cellular multivesicular endosome 
(MVE) and apoptotic bodies originating from the shedding cells during 
programmed cell death (Raposo and Stoorvogel 2013). Most studies have not 
clearly defined the origin of EVs since the development of methods to 
discriminate between exosomes and microvesicles constitutes a major 
challenge. Differences in properties such as size, morphology, buoyant 
density, and protein composition seem insufficient for a definitive distinction 
(Bobrie et al. 2011). EVs participate in cell-to-cell communication by 
transferring functionally relevant biomolecules such as proteins, mRNA, and 
miRNA (Ragni et al. 2017, Tomasoni et al. 2013, Valadi et al. 2007). 
MSC mediated immunomodulative and angiogenesis promoting effects 
are decreased when transwell systems are used, indicating that at least some 
of the MSC functions are mediated via contact dependent signaling. Besides 
direct protein-interaction mediated intercellular signaling, MSCs have also 
been shown to utilize tunneling nanotubes to transfer molecules and even 
cell organelles such as mitochondria to the target cells such as macrophages 
and T-cells (Jackson et al. 2016, Liu et al. 2014, Matula et al. 2016).  
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Figure 3 MSCs repair injured or damaged tissues by diverse mechanisms. A. Differentiation 
into different cell types to replace cells in the damaged tissue. B. Intercellular signaling includes 
paracrine and contact-dependent mechanisms. Paracrine mechanisms include secretion of 
soluble molecules such as growth factors, hormones and cytokines and secretion of extracellular 
vesicles to transfer protein/peptides, RNA or other molecules. Contact-dependent signaling is 
mediated by surface proteins or tunneling nanotubes. Abbreviations: PGE2, prostaglandin E2; 
sHLA-G5, soluble human leukocyte antigen G5; TGFβ, transforming growth factor beta; IL-6, 
interleukin-6; SDF-1, stromal-derived factor-1; IGF-1, insulin-like growth factor-1; HGF, 
hepatocyte growth factor; VEGF, vascular endothelial growth factor; PDGF, platelet-derived 
growth factor; ANG1, angiopoietin-1. Figure is adapted from (Spees et al. 2016) under license 
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The beneficial properties of MSCs are utilized for various indications in 
clinical trials and the number of ongoing trial is continuously increasing. As 
of August 2016, the clinical trials database (http://www.clinicaltrials.gov) 
showed 418 clinical trials using MSCs for various indications (Figure 4). 
Bone marrow is still the most commonly used source of MSCs (n=204), but 
other tissues, especially adipose tissue (n=79) and umbilical cord (n=53), are 
also often used. In particular, interest in adipose tissue as autologous source 
of MSCs is increasing. 
Most of the clinical trials are in Phase I (safety studies, n=147) or in 
combined Phase I and II (n=151). A total of 84 studies have reached phase II 
(proof of concept for human patients). Only 18 studies are currently in phase 
III (comparison of new treatment with standard treatment) and 13 studies 
are in combined Phase II and Phase III. In general, MSCs appear to be well 
tolerated and safe. In meta-analysis, a significant association between MSC 
administration and transient fever was reported (Lalu et al. 2012). 
Fetal bovine serum (FBS) has historically been considered essential for 
obtaining MSCs of high quantity and quality. However, FBS carries the risk 
of transmitting immunogenic xenoproteins or infectious agents. The 
development of human supplements, such as platelet rich plasma or platelet 
lysate, has led supplements to produce high-quality clinical-grade MSCs for 
therapeutic applications (Bieback et al. 2009, Juhl et al. 2016, Laitinen et al. 
2016a). Also, the actual composition of nutrients in FBS has not been 
optimized and especially the fatty acid composition may not be optimal in 
terms of the best possible therapeutic outcome (Tigistu-Sahle et al. 2017). 
Despite the availability of animal serum-free culture methods, FBS is still the 
most commonly used medium supplement in expansion of MSCs since only 
seven clinical trials reported the usage of a human medium supplement. 
The most significant results on the immunosuppressive effects of MSCs so 
far have been observed in the treatment of acute graft versus host diseases 
(GVHD) after allogenic hematopoietic stem cell transplantation (Le Blanc et 
al. 2008). After the first trials, MSCs have been shown to be a promising new 
therapy for both acute and chronic steroid resistant GVHD (Chen et al. 
2015). Recently, the use of MSCs has been expanded to other hematological 
disorders (Cle et al. 2015) and co-transplantation in allogenic HSC 
transplantation to prevent GVHD or improve the engraftment (Liu et al. 
2011a). Based on their ability to modulate T-cell proliferation and function, 
MSCs have also been proposed as a therapeutic tool for Chron’s disease 
(Forbes et al. 2014), autoimmune diseases (Wang et al. 2014), diabetes 
(Carlsson et al. 2015), renal transplantation rejections (Reinders et al. 2015), 
and in the treatment of various immune-mediated neurodegenerative 
disorders such as amyotrophic lateral sclerosis (Oh et al. 2015, Petrou et al. 
2016) and multiple sclerosis (Karussis et al. 2010, Llufriu et al. 2014).  
Osteoarthitis is a disorder that leads to cartilage damage associated with 
synovial inflammation. The immunomodulatory capacity of AT-MSCs is used 
to alleviate osteoarthritis in the knee and other sites (Pers et al. 2016). 
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The regenerative potential and particularly the differentiation capacity 
into osteoblasts exhibited by MSCs have given rise to studies investigating 
their therapeutic use in osteogenesis imperfecta (Gotherstrom et al. 2014). 
Even though the majority of the experimental evidence on differentiation 
capacity of MSCs comes from in vitro experiments, there are also results 
indicating that engrafted MSCs can promote tissue regeneration by 
differentiating into tissue-specific cells in vivo such as cardiomyocytes 
needed for repair of injured tissues (Gojo et al. 2003). Later it has been 
shown that the trophic effects of MSCs are of great significance in tissue 
regeneration. After engraftment, MSCs produce a number of molecules that 
can not only reduce inflammation but also stimulate tissue generation by 
promoting cell-to-cell connections (Plotnikov et al. 2008). The regenerative 
potential of MSCs is nowadays harnessed to treat various conditions such as, 
ischemic cardiomyopathy (Hare et al. 2009), liver diseases (Shi et al. 2012, 
Zhang et al. 2012), spinal cord injury (Mendonca et al. 2014, Satti et al. 
2016), and stroke (Honmou et al. 2011, Lee et al. 2010). 
 
 
Figure 4 Summary of clinical trials using MSCs. The data were derived from ClinicalTrials.gov 
(http://www.clinicaltrials.gov) on August 8, 2016. Keywords “mesenchymal stromal cells OR 
mesenchymal stem cells” were used. Trials with unknown status or terminated before enrolment 
were excluded from the analysis, n=418 A. Tissue sources of MSCs currently used. “Not 
specified” category includes trials that did not clearly state their cell sources including trademark 
products. “Other” includes tissue sources such as menstrual blood or skin. B. Donor type of 
MSCs used in clinical trials C. Current phases of clinical trials D. Clinical indications that are 
targeted with MSC therapy. Disorders are divided in larger categories. 
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MSC therapy in acute kidney injury 
 
Acute kidney injury (AKI) is a common clinical syndrome in hospitalized 
patients, particularly those with chronic kidney disease, diabetes, and 
vascular diseases. Furthermore, 30-40% of all cases of AKI observed during 
hospitalization occur in the context of surgical operations and especially after 
cardiovascular surgery. AKI is currently defined as a rapid decrease in kidney 
function as measured by an increase in serum creatinine and/or urine output 
(Erpicum et al. 2014, Tögel and Westenfelder 2012). AKI commonly involves 
tubular damage called acute tubular necrosis (ATN) and a reduced 
glomerular filtration rate caused by transient ischemia and reperfusion (I/R) 
(Schrier et al. 2004). Pathophysiology of I/R consists of diverse metabolic 
and inflammatory events. A rapid drop in oxygen and nutrition 
concentrations leads to vasoconstriction, separation of tubular cells and 
obstruction of tubules. Even though oxygen supply limits oxidative 
phosphorylation, anaerobic glycolysis allows a residual production of ATP. 
However, the formation of lactate results in the acidification of cell cytosol, 
finally leading to the disruption of mitochondrion and cell functions. In 
addition, the lack of energy delivery induces morphologic changes, including 
disruption of the cytoskeleton and intercellular tight junctions, loss of cell 
polarity and the translocation of the Na+/K+ATPase transporter from the 
basolateral membrane to the cytoplasm causing apoptosis of tubular cells 
(Schrier et al. 2004, Seo-Mayer et al. 2011). 
Both innate and adaptive immune responses are important in the 
pathology of ischemic kidney injury. Injured tubular epithelium releases pro-
inflammatory cytokines and chemokines, which aid in recruiting immune 
cells. Epithelial cells also express adhesion molecules, toll-like receptors 
(TLRs), complement and complement receptors, and T cell costimulatory 
molecules, which activate the immune cells (Bonventre and Yang 2011). T 
cells are key mediators in the renal IRI (Ascon et al. 2006). The recruitment 
of regulatory T cells is one of the anti-inflammatory mechanisms in the 
recovery of an injured kidney (Gandolfo et al. 2009, Kinsey et al. 2010). 
Recently, the importance of TLR9 in Treg recruitment in AKI was 
demonstrated (Alikhan et al. 2016). 
Currently, available treatments are largely supportive, including fluid 
maintenance, vasoactive drugs, cytoprotective therapy, and dialysis (Thakar 
2013). There is a clear need for novel therapeutic approaches to increase the 
survival rate in AKI. Even when injured, the kidney has a great regeneration 
potential. MSCs could offer an innovative approach to the promotion of 
proliferation and differentiation of progenitor cells inside the kidney and 
inhibition of inflammation. Previous studies based on animal models have 
shown the effectiveness of MSCs derived from bone marrow (Alfarano et al. 
2012, Morigi et al. 2008, Wise et al. 2014), adipose tissue (Furuichi et al. 
2012), and umbilical cord blood (Jang et al. 2014) in the treatment of IRI. In 
addition, other models using glycerol (Herrera et al. 2004, Qian et al. 2008) 
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or cisplatin (Qi and Wu 2013) to induce kidney injury have been used to 
study the therapeutic effect of MSCs. In the initial clinical trials, the safety 
and feasibility of MSC therapy were assessed in patients with a high risk of 
developing AKI after cardiac surgery (Gooch et al. 2008, Tögel and 
Westenfelder 2012). Two phase II trials aimed at showing the efficacy of 
MSC treatment in AKI patients are on-going (NCT01275612 and 
NCT01602328), but no results have been reported so far for these trials. 
The mechanisms of MSCs-mediated renoprotective functions are divided 
into differentiation-dependent and differentiation-independent mechanisms. 
Although studies in both animals and humans have shown that MSCs are 
able to differentiate into tubular epithelial cells (Herrera et al. 2004, Morigi 
et al. 2004), the primary modes of action are considered to be paracrine and 
also endocrine since only very limited engraftment and differentiation into 
target cells have been observed in vivo (Morigi et al. 2008). More recently, 
Zhao et al. (2014a) showed that an intrarenal injection of MSCs resulted in 
differentiation into vascular endothelial cells indicating that at least part of 
the regenerative potential could after all be differentiation-dependent. 
The paracrine action of MSCs involves the delivery of trophic factors and 
anti-inflammatory soluble molecules to the kidney. AKI causes a significant 
up-regulation of SDF-1 and hyaluronic acid in the kidney, thus resembling 
the microenvironment in the bone marrow niche. Infused MSCs are able to 
home to the injured kidney through the use of homing receptors CXCR4 
(SDF-1 receptor) and CD44 (the hyaluronic acid receptor) (Herrera et al. 
2007, Tögel et al. 2005b). The expression of CXCR4, however, decreases 
during in vitro cell culture, thus reducing the homing ability of transfused 
MSCs. There is an elevated expression of transforming growth factor β (TGF 
β) in I/R injured kidneys, which induces the expression of CXCR4 on cell 
membranes, resulting in enhanced homing of MSCs (Si et al. 2015). Also, in 
vitro hypoxic preconditioning is shown to increase the expression of CXCR4, 
further enhancing the homing and therapeutic effects in AKI (Liu et al. 
2012a). 
MSCs in situ adapt their gene expression profile in response to 
extracellular signals and, via cross-talk, regulate the gene expression of renal 
epithelial, endothelial, and immune cells. MSCs down-regulate the 
expression of pro-inflammatory TNF-α, IL-1β, and IFN-γ, and significantly 
up-regulate gene expression of anti-inflammatory cytokine IL-10, 
antiapoptotic BCL-2, basic fibroblast growth factor (bFGF), and 
transforming growth factor α (TGFα) in order to accelerate the repair process 
in the injured kidney (Tögel et al. 2005a). 
MSCs release vascular endothelial growth factor (VEGF), insulin-like 
growth factor 1 (IGF-1), hepatocyte growth factor (HGF), and SDF-1, which 
exert anti-apoptotic, mitogenic, and angiogenic functions in AKI (Imberti et 
al. 2007, Tögel et al. 2009, Zarjou et al. 2011). The secretion of anti-
inflammatory factors, such as prostaglandin E2 (PGE2), TGFβ, HLA-G5, and 
HGF, can down-regulate several types of immune cells, such as T cells (both 
Review of the literature 
22 
CD4+ and CD8+), NK cells, B cells, dendritic cells, and macrophages. The 
relevance of these factors in IRI has yet to be fully studied. In addition to 
soluble molecules, MSCs release extracellular vesicles as part of their 
paracrine mechanisms to transfer mRNA, miRNA, and other molecules to 
the injured cells to protect against AKI or to induce recovery (Bruno et al. 
2009, Collino et al. 2015, Tomasoni et al. 2013). In contrast, Xing et al. 
(2014) used MSC conditioned medium to show no effect in AKI. 
In IRI induced AKI, the lack of oxygen causes one of the most immediate 
effects by depressing the oxidative phosphorylation in mitochondria. 
Recently, MSCs have been shown to fully restore mitochondrial respiration, 
resulting in enhanced ATP synthesis in kidney mitochondrion after I/R 
(Beiral et al. 2014). 
2.3 Immunomodulative mechanisms of MSCs 
MSCs affect both innate and adaptive immune systems by suppressing the 
proliferation of T cells, maturation and antigen presentation of dendritic 
cells, and the proliferation and antibody production of B cells, by inhibiting 
the cytokine production and cytotoxicity of NK cells, and by promoting the 
generation of regulatory T cells. The full picture of how MSCs regulate 
different immune systems remains unclear. A number of mechanisms have 
been reported, involving cell-to-cell contact, secretion of soluble factors and 
extracellular vesicles, and induction of anergy, apoptosis, and regulatory cells 
(Figure 5). In the immune system, immune cells and non-immune cells are 
linked together in a complex network of cytokine production and responses. 
MSCs are not considered to be immune cells, but should be regarded as 
coordinators of immune system (Hoogduijn 2015). 
When lymphocytes are activated, they proliferate and differentiate to 
execute their effector functions. Various stimulants can be used to activate T 
cell proliferation. MSCs are shown to inhibit dose dependently T-cell 
proliferation induced by alloantigens (Krampera et al. 2006, Meisel et al. 
2004, Ryan et al. 2007), polyclonal activators such as PHA (Aggarwal and 
Pittenger 2005) and antiCD3/CD28 (Castro-Manrreza et al. 2014, Melief et 
al. 2013). This immunosuppressive capacity has been demonstrated by using 
both peripheral blood mononuclear cells and populations enriched in CD3+, 
CD4+, and CD8+ T cells. Besides proliferation, MSCs can modulate T cell 
differentiation into subtypes characterized by the secretion of a set of 
cytokines. For instance, MSCs inhibit the production of proinflammatory 
cytokines IL-17, IL-22, IFNγ, and TNFα and the differentiation of naïve CD4+ 
lymphocytes to Th17 cells. Additionally, MSCs promote the production of 
IL10 and the expression of transcription factor Foxp3, indicating 
differentiation toward Treg phenotype (Ghannam et al. 2010). Recently, it 
has been suggested that these phenomena are not independent; instead, 
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MSCs are able to convert Th17 cells into cells with a Treg phenotype 
(Obermajer et al. 2014). 
B lymphocytes are involved in the adaptive immune response. These cells 
are responsible for humoral immunity and are specialized in antibody 
production. MSCs from healthy human donors can inhibit normal B cell 
proliferation, differentiation, and antibody secretion (Corcione et al. 2006). 
When purified mouse B cells were used, MSCs seemed to induce the 
proliferation and differentiation of B cells (Traggiai et al. 2008). This 
phenomenon can be explained by cross-talk between T and B cells. The 
signals arising from T cells are required for MSCs to apply their 
immunomodulatory effects on B cells (Rosado et al. 2015). 
Dendritic cells (DC) are the most important antigen presenting cells in the 
body. DCs must undergo maturation to initiate an appropriate immune 
response and during this process, DCs increase their expression of HLA class 
II molecules and costimulatory molecules CD80 and CD86. MSCs have an 
effect on the recruitment, maturation, and function of DCs. MSCs can 
significantly reduce monocyte differentiation into DCs, affecting the 
upregulation of costimulatory molecules and other dendritic cell markers 
(Spaggiari et al. 2009, Jiang et al. 2005). 
Within the innate immune system, macrophages are key players in 
initiating and controlling inflammation. Monocytes arriving at the site of 
inflammation can differentiate into activated pro-inflammatory M1 
macrophages or convert into alternatively activated anti-inflammatory M2 
macrophages (Mantovani et al. 2013). The production of proinflammatory 
M1 macrophages or T cells may activate MSCs and trigger the release of 
mediators that skew the differentiation of monocyte toward M2 profile (Le 
Blanc and Mougiakakos 2012). Together with macrophages, NK cells are 
important in innate immunity and participate in the body’s defenses against 
infections and cancer. MSCs affect the phenotype, proliferation, cytotoxicity, 
and cytokine production of NK cells (Sotiropoulou et al. 2006, Spaggiari et 
al. 2008). Neutrophils act as first line defense in the innate immunity against 
pathogens. MSCs’ interaction with macrophages and NK cells has been 
described in detail, but neutrophils have been studied to a lesser extent. 
Recently, Jiang et al. (2016) showed that MSCs suppress respiratory burst, 
apoptosis, peroxidase, and protease release in neutrophils in vitro.  
Currently, several mechanisms involving both cell-cell contact-dependent 
and contact-independent mechanisms for MSC immunoregulation have been 
described. However, the results are derived form co-culture in vitro assays, 
and only little is known about MSCs’ immunoregulative capacity and 
functions in vivo (Consentius et al. 2015).  
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Figure 5 Immunomodulatory effects of MSCs and potential mechanisms in response to 
inflammatory signals. CTL, Cytotoxic T lymphocyte; HGF, hepatocyte growth factor; HLA, HO, 
hemioxygenase; human leukocyte antigen; IFN; interferon, IL, interleukin; IDO, indoleamine 2,3-
dioxygenase; LIF, Leukocyte inhibitory factor; NK, natural killer; PGE2, prostaglandin E2; PD-1, 
Programmed death-1; TLR, Toll-like receptor 
2.3.1 Soluble factors 
MSCs regulate immune cells via both cellular contact-dependent and 
independent mechanisms. The first molecules described in MSC-mediated 
immunoregulation of alloantigen-activated T-lymphocytes were TGFβ1 and 
HGF (Di Nicola et al. 2002). MSCs constitutively express TGFβ1 and HGF, 
which seem to act synergistically (Ryan et al. 2007). TGFβ1 is involved in 
MSC-mediated generation of CD4+, CD25+Foxp3+ Tregs (English et al. 
2009) and in decreased proliferation of NK cells (Spaggiari et al. 2008). 
HLAG molecules are non-classic HLA molecules that have a limited 
number of allelic polymorphisms and are expressed in specific tissues. MSCs 
express the soluble isoform sHLA-G5, which expression is increased by IL-
10. The secretion of HLA-G5, which requires direct cell- to- cell contact, has 
been demonstrated to suppress T-cell proliferation, probably via Treg 
induction. In addition to adaptive immunity, HLA-G5 regulates innate 
immunity by decreasing the cytotoxicity and IFNγ production of NK cells 
(Selmani et al. 2008).  
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Several other soluble molecules are identified as modulators of MSC-
mediated T-cell proliferation including Galectins 1, -3, -9, (Gieseke et al. 
2013, Lepelletier et al. 2010, Sioud et al. 2011), Semaphorin 3A, (Lepelletier 
et al. 2010), LIF1 (Nasef et al. 2008), and PD1 ligands (Davies et al. 2017). 
Despite several molecules and factors having been described so far, MSCs’ 
immunodulative mechanisms are not yet fully understood. Most of these 
molecules were identified in in vitro blocking assays, and their relevance in 
vivo remains to be investigated. 
 
Prostaglandin E2 
 
Membrane lipids not only are structural components of cell membranes but 
also mediate biological signals through G-protein activators, second 
messengers, and nuclear receptors. The structures of glycerophospholipids 
(GPL), an important group of membrane lipids, are extensively varied. As a 
consequence of the combination of different polar head groups assembled 
together with various acyl, alkyl, or alkenyl chains, a single cell can contain 
more than a thousand different GPL molecular species. Cellular mediators 
such as inositol phosphates, diacylglycerols, lysophospholipids, ceramides, 
cleaved fatty acids, or their derivates are released from membrane lipids. 
These mediators have been shown to have a crucial role in many 
physiological processes, including the regulation of immune system and 
inflammation. The essential polyunsaturated fatty acid (PUFA) arachidonic 
acid (20:4n-6, AA) is found primarily at the sn-2 position of most membrane 
phospholipids. It is a precursor for the synthesis of prostaglandins, 
thromboxanes, and leukotrienes (Funk 2001). PGE2 is one of the lipid 
mediators produced from 20:4n-6 in a reaction catalyzed by COX1 and COX2 
enzymes. These enzymes are constitutively expressed in MSCs, although 
COX2 expression increases dramatically in an inflammatory environment. 
Similarly, the production of PGE2 is induced by IFNγ and TNFα (Aggarwal 
and Pittenger 2005). PGE2 has been shown to have pleiotropic effects on 
immune cells. PGE2 inhibits the proliferation of T lymphocytes (Aggarwal 
and Pittenger 2005) and B lymphocytes (Hermankova et al. 2016) and 
promotes Treg differentiation (English et al. 2009). PGE2 is involved in a 
decrease in differentiation of DCs from monocytes (Spaggiari et al. 2009) 
and a decrease in proliferation and cytotoxic activity of IL2 activated NK cells 
(Spaggiari et al. 2008). 
 
Extracellular vesicles 
 
Besides soluble molecules, MSCs secrete EVs that have been demonstrated to 
possess immunoregulative properties. EVs collected from MSC-conditioned 
medium suppressed the production of pro-inflammatory cytokines TNFα 
and IL1β but increased the concentration of TGFβ during in vitro culture. In 
addition, EVs reduced the differentiation of Th17 cells while promoting Treg 
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differentiation (Chen et al. 2016). Del Fattore et al. (2015) reported similar 
results showing that MSC-EVs promote Treg induction and IL-10 production 
but do not inhibit the proliferation of CD3+ T-cells. As IDO seems to be one 
of the main mechanisms in MSC mediated immunoregulation, MSC-EVs 
mediate their functions through IDO-independent mechanisms (Chen et al. 
2016, Del Fattore et al. 2015). One possible mechanism might involve CD73 
and CD39 enzymatic activity. Kerkelä et al. (2016) showed that both MSCs 
and MSC-derived EVs produce adenosine from adenosine monophosphate. 
Recently, Di Trapani et al. (2016) elegantly demonstrated the uptake of 
MSC-derived EVs into T, B and NK cells and that the uptake on the effector 
cells was enhanced by cytokine priming. Most interestingly, only the 
inhibition of endocytic vesicle production pathway influenced 
immunomodulation. In addition to regulation of lymphocytes, MSC-EVs 
have been shown to promote the macrophage polarization toward M2 
phenotype (Lo Sicco et al. 2017). 
2.3.2 Contact dependent mechanisms 
The immunosuppressive capacity of MSCs can only partially be explained by 
soluble factors. However, in human MSCs only few contact-dependent 
mechanisms have been identified so far. MSCs express notch ligand Jagged-
1, and with the addition of Jagged-1 neutralizing antibody, MSCs recovered 
their ability to suppress the proliferation of CD4+ T cells (Liotta et al. 2008). 
In inflammatory conditions, MSCs inhibit the differentiation and function of 
Th17 cells through cell-cell contact, mediated by joint participation of CCR6 
and CD11a/CD18, expressed by T-cells, and their respective ligands CCL20 
and CD54 (Ghannam et al. 2010).  
Instead, in mouse models contact dependent mechanisms have been 
studied more extensively. In addition to PD1/PD-L1 pathway, which 
participates in the inhibition of T and B cell activation (Augello et al. 2005, 
Hermankova et al. 2016), other membrane proteins, such as Fas-FasL and 
adhesion molecules intercellular adhesion molecule 1 (ICAM1), and vascular 
cell adhesion molecule 1 (VCAM1), have been suggested to mediate MSC 
immunoregulation (Akiyama et al. 2012, Ren et al. 2010). 
2.3.3  Enzymatic activity of MSCs 
In human MSCs, tryptophan degrading enzyme indoleamine 2,3-dioxygenase 
(IDO) represents the main pathway of immunosuppression. Tryptophan 
starvation is the primary reason for T-cell inactivation, but tryptophan 
metabolites, such as kynurenine, also regulate the proliferation and survival 
of T-cells (Mellor and Munn 2004). IDO has been reported to have an 
immunosuppressive role in many other settings including cancer (Katz et al. 
2008). Meisel et al. (2004) were the first to show that MSCs express IDO in 
an IFNγ-dependent manner and thus identified IDO-mediated tryptophan 
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catabolism as a novel T-cell inhibitory mechanism of MSCs. Recently IDO-
independent mechanisms induced by IFNγ using P7H1 and B7DC/PD1 
pathways were demonstrated (Chinnadurai et al. 2014). 
Extracellular adenosine triphosphate (ATP) and adenosine (Ado) are 
involved in inflammatory processes. ATP is a mostly pro-inflammatory 
molecule and is released during hypoxic conditions and by necrotic cells, as 
well as by activated immune cells and endothelial cells. Extracellular ATP can 
be hydrolyzed into Ado by a two-step enzymatic process catalyzed by two 
ectonucleotidases, CD39 and CD73, which are expressed in many tissues. 
Regulatory T-cells (Tregs) are shown to utilize CD39 CD73 machinery to 
inhibit T-cell proliferation and cytokine production (Deaglio et al. 2007, 
Schuler et al. 2014). Human MSCs express constitutively CD73, but CD39 
expression levels vary according to the tissue source (Kerkelä et al. 2016). It 
has been demonstrated that this pathway is at least partially responsible for 
T-cell suppression of MSCs (Huang et al. 2017, Huang et al. 2017, Kerkelä et 
al. 2016, Saldanha-Araujo et al. 2011).  
Hemioxygenases (HOs) are intercellular enzymes that catabolize heme 
into biliverdin, CO, and divalent iron. HO-1 is constitutively expressed in 
MSCs and has been described as immunoregulative molecule (Najar et al. 
2012). Later studies have demonstrated that HO-1 may act as one mediator 
of suppression of alloactivated T-cells (Chabannes et al. 2007) and induction 
of Tregs (Mougiakakos et al. 2011). 
2.3.4 Extracellular signals and immunomodulation 
In any site of inflammation, there are several cytokines in abundant 
quantities. It has been suggested that MSCs monitor the inflammatory 
environment and switch between pro-inflammatory and anti-inflammatory 
modes of action (Bernardo and Fibbe 2013). There is extensive evidence 
showing that MSCs need to be activated by cytokines produced by T cells, 
macrophages, and NK cells, indicating that communication between MSCs 
and immune cells is reciprocal. Atleast IFNγ on its own is needed for MSC 
activation but it can be accompanied by TNFα, IL-1α, or IL-1β (Aggarwal and 
Pittenger 2005, Ryan et al. 2007, Ryan et al. 2007). Pro-inflammatory 
cytokines induce the expression of HLA II molecules as well as the 
expression or production of several other molecules, such as IDO, galectin-9, 
HO-1, and PGE2 mediating the immunomodulative functions of MSCs (Le 
Blanc et al. 2003, Aggarwal and Pittenger 2005, Gieseke et al. 2013, 
Mougiakakos et al. 2011). Pro-inflammatory preconditioning affects also the 
functionality of MSC-derived EVs (Di Trapani et al. 2016). Interestingly, pro-
inflammatory cytokines alter the phospholipid profile of MSCs, indicating 
that the composition of their membrane lipids is relevant to their function 
(Campos et al. 2016). MSCs express several TLRs, including TLR3 and TLR4, 
and it has been shown that the in vitro activation of specific TLRs affects the 
immunoregulative properties of MSCs. For instance, MSCs induce the 
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formation of Tregs after TLR3 and TLR4 activation in a contact dependent 
manner (Rashedi et al. 2017). Interestingly, it has been suggested that MSCs 
may polarize into either pro-inflammatory or immunosuppressive 
phenotypes depending on the received signals. MSCs primed with TLR3 
ligand poly (I:C) suppressed T-cell proliferation, while the expression of IDO 
and PGE2 production was enhanced. TLR4 activation with 
lipopolysaccharide on the other hand did not induce the production of 
immunosuppressive factors, but TLR3-primed MSCs were in fact pro-
inflammatory (Waterman et al. 2010). Recently, it was demonstrated that 
direct cell-to-cell contact with M1 or M2 macrophages through CD54 also 
changes the immunosuppressive capacity of MSCs (Espagnolle et al. 2017).  
2.3.5 Tissue source 
Bone marrow was the first established source of MSCs. Since this discovery, 
it has remained the most widely investigated and used MSC source in 
therapeutic applications. After being initially found in the bone marrow, 
MSCs have been isolated from various adult and neonatal tissues, of which 
adipose tissue (AT) and birth associated tissues (placenta, umbilical cord UC 
and cord blood CB) are well characterized and commonly used. The 
collection of bone marrow is always an invasive procedure containing a risk 
of infection, thus making alternative sources very attractive. Both birth 
associated tissues, as well as excess adipose tissue removed by liposuction 
can be regarded as biological waste and available for MSC isolation and 
production. 
According to the minimal criteria defining MSCs issued by the ISCT, all 
MSCs should be plastic-adherent spindle-shaped cells with certain 
immunophenotype and tri-lineage differentiation potential (Dominici et al. 
2006). Although MSCs from different sources in general fulfill these criteria, 
there is some variation in the expression of cell surface antigens, 
differentiation potential, and especially in the functional properties of MSCs. 
When initial capacity for colony formation was compared, AT turned out to 
be superior in comparison to CB or BM (Kern et al. 2006). Even though CB 
contains a low number of MSCs and the success rate for isolating MSCs is 
lower, the proliferation rate and capacity of CB and other birth associated 
tissues-derived MSCs are higher (Barlow et al. 2008, Jin et al. 2013, Kern et 
al. 2006). The expression of cell surface antigens seems relatively invariable 
since in most comparative studies no differences in immunophenotype were 
reported. The only observed deviation to the minimal criteria is moderate 
expression of hematopoietic marker CD34 in AT-derived MSCs at least at the 
beginning of in vitro culture (Gronthos et al. 2001, Maumus et al. 2011, 
Mitchell et al. 2006, Pachon-Pena et al. 2011, Traktuev et al. 2008). In 
contrast to immunophenotype, differentiation potential shows more 
variation among MSCs from different sources. In several studies MSCs 
derived from CB and other birth associated tissues show poor or decreased 
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adipogenic potential (Barlow et al. 2008, Castro-Manrreza et al. 2014, Kern 
et al. 2006). 
The origin of MSCs seems to affect more dramatically the epigenetics 
(Reinisch et al. 2015), gene expression (Al-Nbaheen et al. 2013, Kang et al. 
2016, Roson-Burgo et al. 2014, Wagner et al. 2005, Wegmeyer et al. 2013), 
miRNA expression (Ragni et al. 2013), proteomics (Jeon et al. 2016), 
secreted molecules (Pires et al. 2016), and even the content of extracellular 
vesicles (Baglio et al. 2015), but the functional consequences of these 
differences are not yet known. The ability to modulate immune responses is 
one of the most important properties of MSCs. In many comparative studies, 
MSCs collected from different tissues showed very similar 
immunomodulatory properties when a T-cell proliferation assay or a mixed 
lymphocyte reaction was used (Table 1). When cytokine secretion, TLR 
expression, or MSCs’ responses for the inflammatory milieu were studied, 
some differences between MSC from different sources were observed 
(Prasanna et al. 2010, Raicevic et al. 2011b, Roemeling-van Rhijn et al. 
2013b). This indicates that MSCs of different origins may have slightly 
different roles in vivo and more importantly their mechanisms of action may 
be different.  
The comparison of functional properties of MSCs from different sources 
is challenging as the same culture conditions may not be optimal for all the 
MSC types, which may explain some of the differences observed in the 
standardized culture conditions (Fazzina et al. 2016). Furthermore, MSC 
donors show high heterogeneity, which has an impact on MSC functionality 
(Ketterl et al. 2015). When BM-MSCs and AT-MSCs derived from the same 
donor were compared, there was no difference in the inhibition of T-cell or 
NK cell proliferation. However, only BM-derived MSCs were able to inhibit 
NK cell cytotoxicity, and correspondingly AT-MSCs were more potent in 
inhibiting dendritic cell differentiation (Valencia et al. 2016). On the other 
hand, when placenta-derived MSCs were compared with umbilical cord-
derived MSCs from the same donor, placenta-derived MSCs were shown to 
be more efficient in the T cell suppression and also in supporting the growth 
of Treg population (Talwadekar et al. 2015).  
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Table 1 Summary of comparative studies of hMSCs from different tissue sources 
Cell types Parameters Outcome Reference 
AT, BM, PL, UC Angiogenesis BM, PL>AT, UC (Du et al. 2016) 
AT, BM, UC Proliferation 
Differentiation 
T-cell proliferation 
CB=AT>BM 
BM=AT>CB 
BM>UC>AT 
(Fazzina et al. 2016) 
AT, BM, CB, PL Proliferation 
Differentiation 
T-cell proliferation 
PL>AT=BM=CB 
BM=AT (CB,PL 
none) 
BM>AT>CB>PL 
(Heo et al. 2016) 
BM, CB Intestinal ischemic injury 
model 
BM=CB (Jensen et al. 2016) 
BM, WJ, UC T-cell proliferation No differences (Mennan et al. 2016) 
AT, BM T/NK proliferation 
NK cytotoxicity 
Dendritic cell differentiation 
BM=AT 
BM>AT 
AT>BM 
(Valencia et al. 2016) 
BM, UC Immunogenicity 
Lymphocyte proliferation 
BM>UC 
BM<UC 
(Barcia et al. 2015) 
PL, UC T-cell proliferation PL>UC (Talwadekar et al. 
2015) 
BM, CB, PL Adipogenic differentiation 
Osteogenic differentiation 
T-cell proliferation 
BM=PL (CB none) 
BM=CB=PL 
BM=CB>PL 
(Castro-Manrreza et al. 
2014) 
AT, BM, PL, WJ Proliferation 
Adipogenic differentiation 
Osteogenic differentiation 
T-cell proliferation 
WJ>AT>PL>BM 
AT>WJ>BM>PL 
WJ>PL>AT>BM 
WJ>PL>AT>BM 
(Li et al. 2014) 
AT, BM Lymphocyte proliferation AT>BM (at low 
doses) 
(Montespan et al. 
2014) 
AT, BM, CB Proliferation 
Senescence 
Immunosuppression 
CB>BM>AT 
CB<BM=AT 
CB>BM=AT 
(Jin et al. 2013) 
 BM, PL T-cell proliferation 
 
BM=PL (Luan et al. 2013) 
AT, BM Lymphocyte proliferation 
Dendritic cell differentiation 
AT>BM 
AT>BM 
(Melief et al. 2013) 
AT, BM T-cell proliferation AT>BM (Menard 2013) 
AT, BM, WJ T-cell proliferation AT>BM=WJ (Najar et al. 2013) 
AT, BM, UC T/NK cell proliferation 
B cell proliferation 
AT>BM=UC 
AT=BM (UC none) 
(Ribeiro et al. 2013) 
AT, BM T-cell proliferation AT=BM (Roemeling-van Rhijn 
et al. 2013a) 
CB, PL, CL, WJ Proliferation 
Migration 
Adipogenic differentiation 
Immunogenicity 
T-cell proliferation 
CL, CB>PL, WJ 
CL, CB, PL, WJ 
only CL 
CB, WJ>CL,PL 
CL>CB=PL=WJ 
(Stubbendorff et al. 
2013) 
AT, BM Proliferation AT>BM (Xishan et al. 2013) 
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T-cell proliferation BM>AT 
AT, BM, PL T-cell proliferation AT=BM=PL (Lee et al. 2012) 
AT, BM, WJ TLR expression 
T-cell proliferation 
BM=AT, WJ lack 
TLR4 
BM=AT=WT,  
(Raicevic et al. 2011a) 
BM, WJ Lymphocyte proliferation WJ>BM (Prasanna et al. 2010) 
AT, BM Dendritic cell differentiation AT>BM (Ivanova-Todorova et 
al. 2009) 
AT, BM, CB, WJ T-cell proliferation 
 
no differences 
 
(Yoo et al. 2009) 
BM, PL Proliferation 
Adipogenic differentiation 
Osteogenic differentiation 
in vivo toxicity  
PL>BM 
BM>PL 
BM=PL 
BM=PL 
(Barlow et al. 2008) 
AT, BM, CB Isolation success rate 
Proliferation 
Osteogenic differentiation  
Adipogenic differentiation 
AT=BM>CB 
UCB>AT>BM 
No differences 
BM=AT (CB none) 
(Kern et al. 2006) 
AT, BM Immunogenicity 
Lymphocyte proliferation 
BM=AT 
BM=AT 
(Puissant et al. 2005) 
Abbreviations: AT, adipose tissue; BM, bone marrow, CB, cord blood; CL, 
umbilical cord lining cells; PL, placenta; UC, umbilical cord; WJ, Wharton’s 
jelly 
2.4 Replicative senescence of MSCs 
Although MSCs are present in almost all tissues, they are rare in the human 
body. The frequency of MSCs is approximately 0.01-0.001% and their 
number has been shown to decline with age (Caplan 2009). The decline in 
the numbers or potential of stem cell population in adult organs may 
contribute to human aging and even affect the life span of an individual (Van 
Zant and Liang 2003). The effect of donor age on the characteristics of 
hMSCs has yet to be thoroughly studied. Zhou et al. (2008) showed an age-
dependent decrease in proliferation and osteoblast differentiation, and an 
increase in senescence-associated β -galactosidase-positive cells and 
apoptosis in hMSCs. Wagner et al. (2009) show that donor age influences the 
gene expression of MSCs. In rodents, donor age is shown to have a negative 
effect on the growth kinetics as well as capacity to suppress the proliferation 
of CD3+CD4+ T cells (Wu et al. 2014). 
MSCs, like other cultured primary cells, do not grow infinetily, instead the 
cells can undergo a limited number of divisions before reaching senescence 
(Hayflick 1965). At a molecular level, telomere-dependent replicative 
senescence or stress-induced premature senescence is triggered by 
retinoblastoma protein (Rb) or p53 pathways, which activate cyclin-
dependent kinase inhibitors p16 and p21, respectively. These pathways can 
induce each other and work cooperatively (Collado et al. 2007). Senescent 
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cells undergo irreversible growth arrest, but stay metabolically active and 
develop large, flat morphology and typically exhibit a senescence-associated 
β-galactosidase (β-gal) activity. In addition, senescent cells secrete growth 
factors, proteases, and cytokines called senescence associated secreted 
phenotype (SASP) (Figure 6). 
Cell therapy protocols usually require hundreds of thousands hMSCs per 
treatment and because they are so rare in the human body, extensive in vitro 
expansion is required to obtain sufficient numbers of MSCs for cell therapy. 
Long-term expansion may cause continuous changes in gene expression, 
miRNA expression, and DNA metylation patterns of MSCs (Bork et al. 2010, 
Hackl et al. 2010, Schellenberg et al. 2011, Wagner et al. 2008, Wagner et al. 
2009, Yoo et al. 2014). However, these studies were not able to identify 
specific markers for senescent MSCs. Cellular senescence induced by gamma 
radiation affects hMSCs’ immunoregulatory properties both in vitro and in 
vivo (Sepulveda et al. 2014).  
Figure 6 The phenotype of senescent MSCs Abbreviation: SASP, Senescence associated 
secretory phenotype. Figure is adapted from (Turinetto et al. 2016) under license 
???????????????????????????????????????????? 
2.5 MicroRNA regulation in MSCs  
MiRNAs are small non-coding RNAs (20-22 nucleotides) targeting 
messenger RNA (mRNA) for degradation or direct translational repression, 
thus suppressing protein synthesis. To date 2588 distinct miRNA molecules 
have been identified (Griffiths-Jones et al. 2006) 
(http://www.mirbase.org/index.shtml, accessed February 25, 2017), and it 
was estimated that miRNAs regulate 30% of protein coding genes (Lewis et 
al. 2005). One miRNA can target several dozen or even hundreds of mRNAs 
and conversely a single gene has binding sites for several miRNAs in their 3’ 
untranslated regions (Selbach et al. 2008). Development of computational 
and bioinformatics prediction methods has accelerated the reseach on 
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miRNA function and possible targets, revealing the full complexity of the 
miRNA regulation network (Bartel 2009, Lu et al. 2012, Maragkakis et al. 
2009). Currently, there are numerous different prediction tools and 
softwares available, but the high rate of false positive interactions hampers 
the research (Pinzon et al. 2017). MiRNAs have been shown to have a crucial 
role in regulating almost all cellular processes, including cell growth, 
proliferation, and differentiation (Ameres and Zamore 2013, Bartel 2009). 
The role of miRNA regulation in both embryonic and somatic stem cell fate 
and differentiation has been studied extensively during the past few years 
(Ivey et al. 2008, Ong et al. 2015). Most studies investigating the role of 
miRNA regulation in MSCs have focused on osteogenic or adipogenic 
differentiation (Table 2). In hBM-MSCs silencing, Dicer or Drosha inhibits 
both adipogenic and osteogenic differentiation, indicating that miRNAs are 
important regulators of the MSC differentiation (Oskowitz et al. 2008). 
Several miRNAs have been shown to either promote or inhibit the 
osteogenic differentiation of hBM-MSCs. MiR-20a, miR-21, miR-29, miR-
489b, and miR-196 have been shown to promote the osteogenic 
differentiation, whereas miR-27a, miR-31, miR-34a, miR-138, miR-204, 
miR-489, and miR-541 have been shown to have an inhibitory effect (Baglio 
et al. 2013, Candini et al. 2015, Chen et al. 2014, Eguchi et al. 2013, Huang et 
al. 2010, Kapinas et al. 2010, Schoolmeesters et al. 2009, Yang et al. 2013b, 
Zhang et al. 2011). Adipogenesis and osteogenesis are usually presented as 
reciprocally regulated events. Several miRNAs regulate the balance between 
osteogenesis and adipogenesis. MiRNAs, including miR-17-5p and miR-106, 
have been shown to promote adipogenesis and inhibit osteogenesis (Li et al. 
2013a), whereas miR-22 inhibits adipogenesis and stimulates osteogenesis in 
human adipose tissue derived MSCs by repressing its target HDAC6 (Huang 
et al. 2012). MiRNA-mediated regulation of adipogenic differentiation of 
hBM-MSCs is less studied, but it has been shown that miR-369-5p inhibits 
adipogenic differentiation, whereas miR-371 has a strong enhancing effect 
(Bork et al. 2011). 
MiR-21, miR-155, and miRNA family 17~92 are called immunomirs and 
they regulate T-cell differentiation, function, and aging (Kroesen et al. 2015). 
Of these miRNAs, miR-21 is highly expressed in MSCs and its expression has 
been shown to be induced by an anti-inflammatory lipid molecule, resolvin 
D1, which participates in the attenuation of the inflammatory response 
(Recchiuti et al. 2011). MiR-155, on the other hand, inhibits the 
immunosuppressive capacity of MSCs by reducing iNOS expression in mice 
(Xu et al. 2013). MiR-181 is not included in immunomirs, but it has been 
shown to be involved in T- and B-cell development (Ebert et al. 2009). In 
MSCs, elevated miR-181 expression enhances IL-6 and IDO expression, and 
the capability of MSCs to suppress mitogen activated T-cell proliferation was 
also attenuated by miR-181 in, at least partly, IL-6-dependent manner (Liu et 
al. 2012b). 
Review of the literature 
34 
MSCs can be isolated from virtually any tissue (Meirelles et al. 2006). In 
therapeutic applications, BM, AT and CB are the most relevant sources. The 
different origins have been shown to produce MSCs with different 
immunomodulatory properties (Di Trapani et al. 2013), but the results from 
different studies are contradictory (Mattar and Bieback 2015). Since miRNA 
regulation is thought to be one of the key players in MSC differentiation and 
functionality, MSCs have been proposed to have a typical miRNA expression 
pattern, which varies only slightly according to the tissue origin (Ragni et al. 
2013).  
The age of MSC donors and the required in vitro culture of the 
therapeutic MSCs are considered to be a potential factor that may affect the 
properties and the functionality of MSCs and eventually deteriorate the 
therapeutic outcome. The age-dependent changes in miRNA expression may 
be one possible explanation for the observed differences between the aged 
and younger donors. Despite miRNA expression being relatively stable in 
MSCs, some age-dependent miRNA expression changes have been previously 
identified (Candini et al. 2015). Interestingly, the miRNA expression of hBM-
MSCs and hAT-MSCs is differently affected by the donor age (Pandey et al. 
2011). Replicative senescence has also been described to be at least partly 
driven by miRNA regulation (Wagner et al. 2008, Yoo et al. 2014). The 
results are, however, contradictory and the influence of donor age on 
senescence has not yet been thoroughly studied. 
 
Table 2 MiRNAs in regulation of hMSCs 
miRNA MSC 
source 
Target 
gene 
Effects Reference 
Differentiation 
miR-10a BM KLF4 Promote differentiation (Li et al. 2013b) 
miR-22 AT HDAC6 Inhibit adipogenesis 
Promote osteogenesis 
(Huang et al. 2012) 
miR-21 AT SPRY2, 
TGFBR2 
Promote adipogenesis (Kim et al. 2009a, 
Mei et al. 2013) 
miR-30 AT RUNX2 Promote adipogenesis (Zaragosi et al. 
2011) 
let-7 BM IL-6 Inhibit adipogenesis (Sung et al. 2013) 
miR-27 AT PPARγ, PHB Inhibit adipogenesis (Kang et al. 2013, 
Karbiener et al. 
2009) 
miR-23b BM PRKACB Promote chondrogenesis (Ham et al. 2012) 
let-7, 
miR-24, 
miR-125b, 
miR-138 
BM n.d Promote osteogenesis 
through PDGF pathway  
(Goff et al. 2008) 
miR-148b BM n.d Promote osteogenesis (Schoolmeesters et 
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al. 2009) 
miR-17 PO SMURF-1 Promote osteogenesis (Liu et al. 2011b) 
miR-196a AT HOXC8  Promote osteogenesis (Kim et al. 2009b) 
miR-20a BM PPARγ, 
BAMBI, 
CRIM1 
Promote osteogenesis (Zhang et al. 2011) 
miR-21 AT, BM SPRY1/2, 
SPRY2 
Promote osteogenesis (Mei et al. 2013, 
Yang et al. 2013a) 
miR-218 AT SFRP2, 
DKK2 
Promote osteogenesis (Zhang et al. 2014) 
miR-29a BM DKK1, 
KREMEN2, 
SFRP2 
Promote osteogenesis (Kapinas et al. 
2010) 
miR-346 BM GSK-3β Promote osteogenesis (Wang et al. 2013) 
miR-26a AT SMAD1 Inhibit osteogenesis (Luzi et al. 2008) 
miR-27a BM SATB2 Inhibit osteogenesis (Schoolmeesters et 
al. 2009) 
miR-31 BM OSTERIX Inhibit osteogenesis (Baglio et al. 2013, 
Gao et al. 2011) 
miR-100 AT BMPR2 Inhibit osteogenesis (Zeng et al. 2012) 
miR-138 BM FAK Inhibit osteogenesis (Eskildsen et al. 
2011) 
Proliferation/senescence 
miR-10a BM KLF4 Inhibit senescence (Li et al. 2013b) 
miR-16 PL CCNE1 Inhibit proliferation (Wang et al. 2012) 
miR-196a BM HOXB7 Inhibit proliferation (Candini et al. 
2015) 
Immune regulation 
miR-181 BM TGFBR1, 
TGFBRAP1 
Inhibit immune 
suppression 
(Liu et al. 2012b) 
Angiogenesis 
miR-16 PL  CCNE1 Inhibit angiogenic potential  (Wang et al. 2012) 
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3 AIMS OF THE STUDY 
In general, the aim of this study was to investigate the regulatory network 
between cell cycle, immunosuppression, and membrane lipids of MSCs by 
analyzing immunosuppressive capacity, phospholipid composition, and gene 
expression changes related to expansion and donor age. 
 
The specific aims of this study were: 
 
1. To investigate the immunosuppressive capacity of BM-MSCs and CB-
MSCs 
2. To investigate the role of membrane lipid composition in the 
functionality of MSCs 
3. To investigate the effect of IFNγ stimulus on the secretion and 
function of CB-MSC derived extracellular vesicles 
4. To analyze age- and expansion-induced changes in phospholipid 
composition, mRNA, or miRNA expression 
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4 MATERIALS AND METHODS 
Materials and methods used in this study are summarized in Table 3. More 
detailed information can be found in the original publications. 
Table 3 Summary of methods used in the study. The original publications are referred 
to using their Roman numerals I-III 
Experimental procedure Publication 
Cell culture I, II and III 
Co-culture assays  I and III 
Isolation and size determination of extracellular vesicles III 
Experimental animal procedures III 
Gas chromatographic analysis of fatty acids I 
Mass spectrometric lipidomis I  
Mass spectrometric proteomics III 
Gene expression analysis I and II 
Senescence indicators I 
Bioinformatics and Statistical analysis I, II and III 
4.1 Cell culture  
Bone marrow derived MSCs (I,II) 
 
Human bone marrow derived MSCs (hBM-MSCs) were obtained from bone 
marrow aspirates taken from the iliac crest or upper femur metaphysis of 
adult patients after written informed consent. All patient protocols were 
approved by the Ethical Committee of Northern Ostrobothnia Hospital 
District or the Ethical Committee of Hospital District of Helsinki and 
Uusimaa. The BM-MSCs collected from donors of different ages (anonymous 
coding) used in this thesis are summarized in Table 4. 
Cells were cultured in minimum essential medium alpha (αMEM), 
supplemented with 20mM HEPES, 10% heat inactivated fetal bovine serum 
(FBS), 2mM L-glutamine, and 100 U/mL penicillin and 100 μg/mL 
streptomycin. The same serum lot was used throughout the study. The cells 
were plated at a density of 1000 cells/cm2, medium was renewed twice a 
week, and the cells were harvested when 70-80% confluent.  
 
Cord blood derived MSCs (III) 
 
Cord blood units were collected at the Helsinki University Central Hospital, 
Department of Obstetrics and Gynaecology, and Helsinki Maternity Hospital. 
All donors gave informed consent and the study protocol was approved by 
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the ethical review board of the Helsinki University Central Hospital and the 
Finnish Red Cross Blood Service. 
Cord blood mononuclear cells were isolated by gradient centrifugation 
and 1 x 106/ cm2 mononuclear cells were plated on fibronectin-coated tissue 
culture plates. The initial CB-MSC establishment was performed under 
hypoxic conditions (5% CO2, 3% O2 at 37°C) in medium containing α-MEM 
with Glutamax™, 10% FBS, 10ng/mL epidermal growth factor, 10ng/mL 
recombinant platelet-derived growth factor, 50nM dexamethasone, 
100U/mL penicillin, and 100μg/mL streptomycin. The cells were allowed to 
adhere overnight, and non-adherent cells were washed with medium 
changes. For further experiments, CB-MSCs were cultured in normoxic 
conditions (5% CO2 and 20% O2 at 37°C) and media was renewed twice a 
week. For flow cytometric analysis, CB-MSCs were trypsinized and 1x105 cells 
were suspended in a staining buffer (0.3% bovine serum albumin in 2 mM 
EDTA-PBS). Fluorscein isothiocyanate (FITC) and allophycocyanin (APC) 
conjugated antibodies against HLA-DR and HLA-ABC were used for direct 
labeling. Appropriate isotype controls were used. 
Table 4 Age and gender of BM-MSCs from young and old donors 
used in the thesis. 
BM-MSC donor Age (year) Gender 
young donors mean age 22.2  
081 20 male 
088 21 male 
089 23 female 
091 23 female 
092 23 male 
old donors mean age 74.6  
164 75 male 
172 72 female 
194 82 male 
271 75 male 
 
Co-culture assays (I, III) 
 
PBMCs were isolated from buffy coats from healthy anonymous blood 
donors (Finnish Red Cross Blood Service) by density gradient centrifugation 
(Ficoll-Pague plus, GE Healthcare) and cryo-preserved for later use. PBMCs 
were chosen over purified T-cells for practical reasons.  Isolation of PBMCs is 
less time-consuming and they provide co-stimulation for T-cells. MSCs or 
EVs were co-cultured with CFSE (5(6)-Carboxyfluorescein diacetate N-
succinimidyl ester) labeled PBMCs. To activate the T-cell proliferation, 
100ng/ml of the anti CD3 antibody clone Hit3a was added to the co-culture. 
T-cell proliferation was recorded after four days of incubation as a dilution of 
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fluorescent dye by flow cytometry. The proliferation of PBMCs without MSCs 
was designated as 100%. 
PBMCs were co-cultured with EVs or CB-MSCs in order to analyze the 
impact on Treg induction. After 7 days of incubation, non-adherent PBMCs 
were harvested and labeled with fluorogenic antibodies, CD4-APC-Cy7, 
CD25-AlexaFluor®647, FOXP3-PerCP5.5) to evaluate the proportion of 
CD4+CD25+FOXP3+ Tregs. Cells were fixed and permeabilized with FOXP3 
Staining Buffer Set (eBioscience) according to the manufacturer's 
instructions and including the blocking step with 2% rat serum. PBMCs 
cultured without MSCs or EVs were used as a control. Appropriate isotype 
controls were used. 
 
Isolation and size determination of extracellular vesicles (III) 
 
Cell culture medium (80-160 ml) was centrifuged at 2,000g for 20 minutes 
in +4°C, succeeded by a further ultracentrifugation step at 100,000g for 1-2 h 
at +4°C. The pellet was washed with phosphate buffered saline (PBS) and 
submitted to a second 1-2h ultracentrifugation in the same conditions. EVs 
were suspended in 50-150μl of PBS and stored at -80°C.  
After centrifugation, EVs were resuspended with PBS, and analyzed with 
the nanoparticle tracking analysis (NTA) instrument LM14C with blue laser 
(405 nm, 60 mW) and a CMOS camera to determine the vesicle size 
distribution and concentration. The data were analyzed with NTA 2.3 
software.  
4.2 Experimental animal procedures 
Eighteen 6- to 7-week-old male Sprague Dawley rats were purchased from 
Charles River Laboratories (Research Models and Services, Sulzfeld, 
Germany). The protocols were approved by the Animal Experimentation 
Committee of the University of Helsinki, Finland, and the Provincial State 
Office of Southern Finland (approval number STH059A), whose standards 
correspond to those of the American Physiological Society. The rats were 
divided into three groups: 1) I/R group (n=8), 2) I/R group + control EV 
(n=5), 3) I/R group + IFNγ-treated EV (n=5). An established model of 
kidney I/R injury was used (Lempiäinen et al. 2012). Twenty-four hours after 
the operation, blood samples were collected from the tail vein under short 
isoflurane anesthesia. Terminal samples were harvested 48 hours after the 
operation; the rats were anesthetized with isoflurane, and blood samples 
were collected from inferior vena cava with a 5ml syringe and 22G needle for 
biochemical measurements. The kidneys were excised, washed with ice-cold 
saline, blotted dry, and weighed. The left kidney was used for histological 
examinations. Tissue samples for histology were fixed in 10% formaline and 
processed to paraffin with routine methodology. 
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4.3 Gas chromatographic analysis of fatty acids  
Total lipids of the BM-MSCs or FBS were extracted according to Folch et al. 
(1957) and converted into FA methyl esters (FAME) by heating with 
methylation reagent (1% H2SO4 in methanol). The dried and concentrated 
FAME solutions were analyzed by gas-liquid chromatography (6890N 
network GC) using flame ionization detection and DB-wax capillary columns 
(30 m, ID 0.25 mm, film 0.25 μm). Agilent Chemstation software was used 
for peak area integration. The identification of the FAMEs was based on 
retention time, mass spectra acquired earlier for similar samples, and 
comparisons with standards of known composition. The FA composition was 
calculated as mol%, and the FAs were marked by using the abbreviations: 
[carbon number]:[number of double bonds] n-[position of the first double 
bond calculated from the methyl end] (e.g. 22:6n-3). 
4.4 Mass spectrometric analysis  
ESI-MS analysis of cellular phospholipids (I) 
 
Total lipids of BM-MSCs were dissolved in chloroform/methanol 1:2 for a 
direct infusion experiment. Several internal standards were used to correct 
for the effects of the polar head group and acyl chain length on the 
instrument response according to previously reported procedures 
(Hermansson et al. 2005, Käkelä et al. 2003, Koivusalo et al. 2001). 
Immediately prior to the mass spectrometry, 1% NH4OH was added and the 
lipid extracts, with the internal standards, were infused to the electrospray 
source of a Quattro Micro triple quadrupole mass spectrometer) at the flow 
rate of 8 μl/min. The collision energy of the instrument was set to 25–65 eV, 
depending on the detection mode, and both negative and positive ion modes 
were used. Argon was used as the collision gas. The PC and lysoPC (precursor 
of 184), PE (neutral loss of 141), PS (neutral loss of 87), and PI (precursor of 
241) species were selectively detected using head-group specific MS/MS 
scanning modes (Brügger et al. 1997, Sullards and Merrill 2001). The acyl 
chain assembly of the major lipid species was confirmed with MS/MS 
techniques. The mass spectra were processed by MassLynx software and the 
individual lipid species quantified by using the internal standards and 
LIMSA software (Haimi et al. 2006). The lipid species were abbreviated: 
[total carbon number in the chains]:[total number of double bonds in the 
chains]. The relative concentrations of the lipid classes were obtained by 
summing up the concentrations of the individual molecular species in a class. 
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Proteomic analysis of EVs (III) 
 
Gel-based proteome analysis of EVs was performed with the liquid 
chromatography-mass spectrometry (LC-MS) of tryptic peptides. Proteins 
from collected EVs were run in a 4-20% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel. The gel was silver 
stained and sliced into pieces. Each gel piece was processed using an in-gel 
reduction, alkylation and trypsin digestion protocol as previously described 
(Shevchenko et al. 2006). Peptides were loaded to precolumn (Protecol 
Guard C18, 150μm, 10mm, 3μm) and separated in a reversed-phase 
analytical column (Acclaim PepMap100 C18, 75μm, 150mm, 3μm) with a 
linear gradient of acetonitrile. Ultimate 3000 LC instrument was operated in 
nano scale with the flow rate of 0.3 μl/min. Eluted peptides were introduced 
to LTQ Orbitrap XL mass spectrometer via ESI Chip interface (in a positive 
ion mode). Data files from MS were processed with Mascot Distiller. The 
processed data was searched with Mascot Server against human proteins in 
UniProtKBdatabase (release 2012_08).  
4.5 Gene expression analysis  
RNA was extracted using Qiagen AllPrep DNA/RNA Mini Kit (Cat. no. 
80204, Qiagen, CA, USA) and a Qiagen supplementary protocol “Purification 
of total RNA containing miRNA from animal cells using the RNAeasy Plus 
Mini Kit “according to the vendor’s instructions.  
Labeled RNAs (800 ng/sample) were hybridized onto Agilent SurePrint 
G3 Human GE 8x60K or Agilent Human miRNA 8x60K microarray (release 
16.0) and then the slides were washed and scanned according to the 
manufacturer’s recommendations. The raw data files (.txt files) were 
imported into the R v. 2.13 software (R Core Team 2015) and preprocessed 
by the BioConductor package limma v.3.4.5 (Smyth 2005). After quality 
control of the data, the median probe intensities were log2 transformed and 
normalized according to the method of the quantiles (Bolstad et al. 2003). 
The probes for the same Entrez Genes or lincRNAs (as of 1st January 2012) 
were averaged. A linear model including the AGE*PASSAGE + SUBJECT + 
DYE terms followed by a moderated t-test was utilized for finding the 
differentially expressed genes (log2 Fold Change >0.58) in the comparisons 
of interest (nominal p-value < 0.01). 
For miRNA expression analyzes, 100 ng of total RNA was reverse-
transcribed and amplified with real-time PCR using miScript-System 
including miScript II RT-Kit, miScript SYBR-Green PCR-Kit, and miScript 
Primer Assay according to the manufacturer's protocol. For endogenous 
control, RNU6 was used. All PCR reactions were performed in triplicate in 
384-well plates and measured by ABI 7900HT detection system. Mean 
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values and standard deviations were calculated and fold changes were 
determined using the ΔΔCT method. 
4.6 Senescense indicators  
Telomere length analysis  
 
Telomere lengths were analyzed by the southern blot analysis of terminal 
restriction fragment (TRF) lengths (Kimura et al. 2010). Genomic DNA from 
snap-freezed cell pellets was purified using the Qiagen DNeasy Blood and 
Tissue Kit and extracted with ethanol. Quality of purified DNA was evaluated 
with 1% agarose gel electrophoresis. Telomere length analysis was performed 
using TeloTAGGG Telomere Length Assay Kit. DNA was digested using RsaI 
and HinfI enzymes and electrophoresed on a 0.8% agarose gel 5V/cm. 
Southern blotting was performed using 20X salium sodium citrate buffer. 
The blot was hybridized overnight using a digoxigenin (DIG)-labeled 
telomere specific probe (TTAGGG) and incubated with an alkaline 
phosphatase-labeled anti-DIG antibody. The blot was then incubated with 
CDP-Star chemiluminescent substrate and exposed to an autoradiography 
film. The autoradiogram was scanned by densitometry and TRF length was 
calculated using ImageJ analysis software (Schneider et al. 2012) according 
to TRF= ΣOD/Σ (ODi/Li), where ODi is optical density and Li is the length of 
the TRF at position i. TRF signals between 3 and 20 kb were used for 
telomere length measurements (Kimura et al. 2010). 
 
Western blotting 
 
Snap-freezed cell pellets were lysed using RIPA–buffer (containing Protease 
Inhibitor Cocktail. 20 μg of total protein was run on a 12% SDS-PAGE gel 
and electrotransferred to Hybond ECL Nitrocellulose membrane. The 
membrane was then blocked with 5% milk in PBS containing 0.1% Tween-20 
and immunoblotted using anti-p16INK4A (1: 800, clone DCS-50) and anti-p21 
(1:250, Clone SXM30). β-actin (1: 8000, monoclonal anti-β-actin, clone AC-
74) was used as a loading control. Polyclonal anti-mouse horseradish 
peroxidase (HRP) conjugated antibody was used as a secondary antibody 
(1:1000). Detection was performed using an enhanced chemiluminescent 
detection system. Quantification of band intensities was performed using GS 
800 densitometer and Quantity One software.  
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4.7 Bioinformatic and statistical analysis  
In study I, the differentially expressed genes were analyzed for significant 
enrichments of GO-BP classes by using R library GOSim v. 1.2.5 using default 
parameters (Frohlich et al. 2007). Enrichments with a p-value <0.01 were 
considered significant. 
In study II, the prediction and functional analysis of putative targets for 
selected miRNAs were performed through the use of QIAGEN’s Ingenuity 
Pathway Analysis (IPA QIAGEN Redwood City, www.qiagen.com/ingenuity). 
In study III, subcellular locations for identified EV proteins were collected 
from UniProt database (as is 23.11.2016). Gene ontology (GO) enrichment 
analysis of identified proteins was performed using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, version 6.7) 
(Huang da et al. 2009) using default settings. 
In all studies results are represented as mean+standard deviation or 
standard error of the mean. In study I statistical significances for the 
differences between BM-MSCs from the young and old donors or early and 
late passages were calculated using student’s paired t-test (* p-value <0.05, 
** p-value< 0.01, *** p-value <0.001). In study II, non-parametric Spearman 
correlation was used to calculate correlation between miRNA expression and 
proliferation of MSCs. In study III, statistically significant differences in 
mean values were tested by one-way analysis of variance (ANOVA) and the 
Tukey’s post-hoc test. Analyses were performed with GraphPad Prism 7.00 
software or using statistical programming software R. 
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5 RESULTS 
5.1 Immunosuppressive properties of MSCs 
In this study, the immunosuppressive properties of both BM-MSCs and CB-
MSC were assessed. MSCs were characterized and they fulfilled the 
established minimal criteria for MSCs (data not shown). One of the key 
functions of MSCs is their capability to suppress T-cell proliferation. The 
immunosuppressive capacity of both MSC types was ascertained by T-cell 
proliferation assay. MSCs were co-cultured with CFSE-labeled PBMCs and T-
cells were activated by CD3 antibody. Proliferation of CFSE labeled cells was 
seen as dilution of CFSE dye measured by flow cytometry. We were able to 
demonstrate that both CB-MSCs and BM-MSCs have strong capacity to 
suppress T-cell proliferation in a dose-dependent manner (Figure 7). 
Umbilical cord blood is an attractive MSC source since it is easily 
available and the collection is non-invasive procedure. The establishment 
and culturing of CB-MSCs are more complicated than that of BM-MSCs. In 
our laboratory, CB-MSC culture medium is supplemented with growth 
factors (EGF, PDGF and dexamethasone (DX)), whereas BM-MSCs are 
cultured with FBS. Since the different culture conditions have modulating 
effects on cell functions, it is impossible to separate the effect of the cell 
source on cell functionality from that of the culture conditions (Laitinen et al. 
2016b). Therefore, direct comparison of the immunosuppressive capacity of 
CB-MSCs and BM-MSCs was not possible. However, the immunomodulative 
properties of MSCs derived from different tissue sources have been 
compared in previous studies (summarized in Table 1), although with 
contradictory results. Heo et al. (2016) reported that BM-MSCs are more 
immunosuppressive than CB-MSCs. On the other hand, Castro-Manreza et 
al. (2014) were not able to see any difference in the immunosuppressive 
capacities. In contrast, Jin et al. (2013) showed that CB-MSCs are actually 
more immunosuppressive than BM-MSCs. While CB-MSCs and BM-MSCs 
were cultured in similar culture conditions in these studies, T-cell 
proliferation was assessed by different methods, rendering a comparison of 
the results difficult. 
In addition to CB, AT, umbilical cord, and placenta are commonly used 
sources of MSCs. Similarly, the results are contradictory and it is impossible 
to prioritize different tissue sources according to their immunosuppressive 
capacity. Notably, in all studies MSCs showed clear capacity to suppress T-
cell proliferation regardless of tissue source and it is therefore other 
characteristics such as availability and proliferative capacity that are more 
important to consider when tissue source is selected. 
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Figure 7 The immunosuppressive capacity of MSCs. A. CB-MSC (n=12) B. BM-MSC (n=16). 
MSCs between passages 4-5 were used. The proliferation of activated PBMCs in absence of 
MSCs was set as 100%. PBMC:MSC ratios 1:20 and 1:50 were used. Results are expressed as 
mean+SD. Unpublished data. 
5.1.1 MSCs have dual role in the regulation of T-cell proliferation 
The possible immunogenicity of MSCs has been one of the concerns in MSC 
therapy.   According to our results, MSCs do not activate T cell proliferation 
in co-culture.  Since MSCs lack the expression of MHCII molecules as well as 
costimulatory molecules, CD80 and CD86, on their surface, they are 
considered to be non-immunogenic, which makes them an excellent 
candidate for cell therapy (Tse et al. 2003).  
In our studies of the immunosuppressive capacity of MSCs, we have used 
PBMCs as responders and activated them with CD3 antibody alone without 
the costimulatory CD28 antibody. We have observed inter-experimental 
variation in the response, and in some experiments T cells do not proliferate 
at all.  When T cells are activated to proliferate, MSCs are highly suppressive. 
However, in the absence of T-cell response MSCs have the opposite, 
stimulatory effect on proliferation (Figure 8). It is noteworthy that in the 
absence of CD3 antibody MSCs do not induce T-cell proliferation.  This may 
be due to the inadequate number of antigen presenting cells with co-
stimulatory molecules. Further, this leads to inadequate proliferation and 
cytokine production by T-cells. In these situations, MSCs may act as pro-
inflammatory factors, stimulating T-cell proliferation as previously described 
in mice (Li et al 2012). 
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Figure 8 MSCs have an inhibitory and stimulatory effect. BM-MSCs were co-cultured 
together with either high responder PBMCs (left) or low responder (right). PBMCs were labeled 
with CFSE and stimulated with antiCD3 antibody. If PBMCs responded poorly to the stimulant 
(low responder), MSCs boosted the T-cell proliferation. When PBMSCs responded efficiently 
(high responder), MSCs had an inhibitory effect on the T-cell proliferation. Unpublished data. 
5.1.2 Effect of IFNγ preconditioning on MSC immunsuppressive 
potential 
The surrounding microenvironment is one of the key regulators of MSC 
functionality. MSCs have been shown to have the ability to react differently 
according to the external stimuli. On the site of inflammation in the injured 
tissue, there are large numbers of different cytokine molecules in 
concentrations that fluctuate depending on the phase of the on-going 
inflammation. Several studies have demonstrated that cytokines, such as 
IFNγ and TNFα, regulate the mRNA expression of IDO and production of 
MSC-derived soluble molecules such as PGE2 (Aggarwal and Pittenger 
2005). For this reason, it has been suggested that priming of MSCs may 
enhance their immunosuppressive capacity and improve the therapeutic 
outcome in clinical application. In our study, we were not able to see any 
influence of IFNγ priming on the immune suppressive capacity of BM-MSCs 
(Figure 9). In the literature, the stimulation times, cytokine concentrations, 
and cytokine cocktails vary greatly. We were able to show that even though 
the immunosuppressive capacity measured by T-cell proliferation was not 
affected, the IFNγ stimulation did increase the expression of HLA I and HLA 
II molecules after 48 hours of stimulation with 100ng/ml IFNγ. This effect 
was not seen after 24 hours of stimulation (Publication III, Fig. S2). 
Stubbendorf et al. (2013) showed that the same effect could be obtained 
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using only 25ng/ml IFNγ. We also used a combination of IFNγ and TNFα to 
stimulate CB-MSC and BM-MSCs. We were not able to see any difference in 
the immunosuppressive capacity of stimulated or control MSCs (data not 
shown). 
 
 
Figure 9 Interferon gamma priming does not improve the immunosuppressive capacity of 
BM-MSCs.  Representative result using BM-MSC: MNC ratio 1:50 is shown.  
5.1.3 Membrane lipid composition of MSCs is related to functionality 
Instead of being passive structural components of the cell membrane, lipids 
are actively involved in cellular signaling events employed in immune 
functions. Membrane lipids act as precursors for lipid mediators that 
regulate immunological events. PGE2, which is produced from 20:4n-6, has 
been shown to have a significant role in MSC-mediated immunosuppression 
(Aggarwal and Pittenger 2005, Chen et al. 2010, Duffy et al. 2011, English et 
al. 2009). The other important FAs, eicosapentaenoic acid (20:5n-3, EPA) 
and docosahexaenoic acid (22:6n-3, DHA), serve as precursor for specialized 
proresolving mediators (SPM). SPMs have been shown to modulate the 
innate immune system and their role in regulating the resolution phase of 
inflammation has recently been described (Serhan et al. 2015). SPMs, such as 
22:6n-3-derived resolvins, not only regulate the innate immunity, as 
previously described, but are also important regulators of adaptive 
immunity. These mediators reduce cytokine production of activated CD4+ 
and CD8+ T cells and inhibit the differentiation of Th17 cells (Chiurchiu et al. 
2016). The immunomodulatory function of MSCs resembles the active 
resolution of inflammation (English 2013) and there is a possibility that 
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SPMs have a role in MSC immunoregulation, which remains to be elucidated 
in future. 
Modern mass spectrometric methods enable researchers to use a 
lipidomic approach to the analysis of cellular lipids as a whole to get a 
broader view of the cellular functions. The lipidomic approach has been used 
to study membrane lipidomes of hematopoietic progenitors and embryonic 
stem cells (Fuchs et al. 2007, Park et al. 2010), but lipidomics studies on 
MSCs are lacking. In this study, we report correlation between membrane 
lipid composition and the immunosuppressive capacity of MSCs. Molecular 
percentage of 20:4n-6 containing phosphatidylcholine (PC) species PC38:4 
and PC38:5 and 20:4n-6 itself correlates negatively (correlation coefficients 
PC38:4, R=-0.91; PC38:5, R=-0.82 and 20:4n-6, R=-0.71) with the 
immunosuppressive capacity of BM-MSCs. (Publication I, Table II) 
Interestingly, a particular n-3 PUFA, 22:6n-3 correlated positively with 
immunosuppressive capacity (R=+0.75). Our result indicates that variation 
in the membrane lipid composition and especially changes in the ratio of 
certain molecular species may have consequences on the MSC functionality. 
The role of composition of lipid mediator precursors in the cell membrane in 
the actual production of the novel SPM mediators needs to be confirmed and 
elucidated in more detail. 
5.1.4 MSC-EVs are immunosuppressive 
To investigate the potential immunomodulative properties of MSC-EVs, we 
co-cultured PBMCs together with isolated CB-MSC-EVs. We showed that CB-
MSC-EVs suppress T-cell proliferation, but the effect is milder (Publication 
III, Fig. 1). In addition to direct suppression of T-cell proliferation, MSCs 
induce the production of regulatory T-cells. When T-cells were co-cultured 
with MSCs or MSC-EVs, the proportion of CD4+CD25+FOXP3+ increased 
(Publication III, Fig. 1). These results indicate that the immunosuppression 
of MSCs may be at least partially mediated by secreted EVs. Gouveia de 
Andrade et al. (2015) showed that BM-MSC and AT-MSC derived EVs failed 
to suppress lymphocyte proliferation. These contradictory results emphasize 
the need for standardization of EV collection and purification methods.  
Di Trapani et al. (2016) have shown that the inhibition of exosomes 
restores T- and B- cell proliferation in the presence of MSCs. This 
phenomenon is more evident in primed MSCs compared to resting MSCs. 
Inhibition of microvesicle shedding and apoptotic body release had no effects 
on effector cell proliferation. In the proteomic analysis, we observed that 
primed MSCs produce EVs that contain different set of Rab proteins 
compared to resting MSCs, indicating that priming induces exosome 
production through MVEs (Publication III, Fig. 7). Taken together, these 
results suggest that MSCs produce immunosuppressive EVs that are 
transferred to effector cells, a phenomenon that is enhanced by priming 
MSCs with TNFα and IFNγ. 
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One of the proposed mechanisms of MSCs is mediated through purinergic 
singaling. CB-MSCs and also CB-MSC-EVs contain CD73 (Publication III, 
Fig. 4). Previously, it has been shown that MSC-EVs exhibit similar activity 
to MSCs in the production of adenosine from adenosine monophosphate 
(Kerkelä et al. 2016). 
5.1.5 Interferon gamma stimulation deteriorates the in vivo 
functionality of MSC-EVs 
MSC-derived EVs have been shown to have a therapeutic effect in AKI. In 
this study, we used an IRI rat model to investigate the protective capacity of 
CB-MSC-EVs. In line with previous studies using glycerol or cisplatin 
induced AKI models, we were able to show that EV-treated rats developed 
less severe AKI. Kidney damage was measured as elevated serum creatinine 
and urea levels at time points 24h and 48h after operation. In rats that were 
treated with MSC-EVs, the dramatic elevation of serum creatinine and urea 
was significantly reduced (Publication III, Fig. 5). The protective effect of 
MSC-EVs was also seen in histopathological analysis of the kidney after 48 
hours. The signs of injured kidney, vast necrosis of tubular cells, tubular 
dilatation, and cast formation, were almost absent in the MSC-EV treated 
rats in comparison to control rats (Publication III, Fig. 6). Our results are 
thus in line with previous studies, demonstrating that MSC-EVs have 
renoprotective effects during the early phase of AKI. In our AKI model, EVs 
were injected to the rats immediately after reperfusion, thus protecting 
kidneys from injury.  
There is convincing evidence that MSCs require extracellular cytokine 
stimulus for complete immunomodulation. MSCs have been shown to 
produce EVs constitutively, but we hypothesized that their quantities and/or 
functionality could be improved with external IFNγ stimulus. We were not 
able to see any difference in the morphology, particle number, or size 
distribution between stimulated and nonstimulated MSCs. (Publication III, 
Fig. 1) Surprisingly, stimulated CB-MSC-EVs did not prevent the 
development of AKI (Publication III, Fig. 5 and 6). 
5.1.6 Proteomic analysis of EVs 
Mass spectrometric proteomic analysis was applied to the analysis of the 
protein content of IFNγ stimulated and nonstimulated CB-MSC-EVs. The 
identified proteins originated from different cellular compartments as 
illustrated in Figure 10. The distributions of stimulated and nonstimulated 
EVs were highly similar, while the protein compositions were different. First 
of all, we were able to identify almost 700 different proteins from stimulated 
MSC-EVs, whereas from control EVs, only 446 proteins were identified 
(Publication III, Fig. 2).  
Results 
50 
According to MS data, only EVstim contained exosome markers CD9, 
CD63, and CD81. MSC markers CD73 and CD90 were found in both EVs. Of 
immunomodulative factors (proteins) shown to mediate MSCs 
immunomodulative functions (see Figure 5), only galectins 1 and 3 were 
identified from the EVs (both stimulated and nonstimulated). On a protein 
family level, we noticed that members of Rab proteins were present in both 
stimulated and nonstimulated EVs. However, the individual proteins were 
mostly different. EVs secreted from stimulated CB-MSCs were linked to 
exocytosis and deeper endosomal pathway (Rab 1, 2, 6, 8). In contrast, EVs 
from nonstimulated MSCs contained Rabs (3, 5, 14, 34) that were more 
related to the early endosomal recycling, near plasma membrane 
(Publication III, Fig. 7). 
 
  
Figure 10 Subcellular locations of MSC-EV proteins. CB-MSC proteome was used as 
reference. Retrieved from Uniprot as is 23.11.2016. Obsolete protein entries were removed from 
the analysis.  
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5.2 Age-induced changes in MSCs 
Prior to clinical use, MSCs need extensive in vitro expansion. In order to 
investigate the effects of long-term cell culture on the functional properties of 
MSCs, we isolated BM-MSCs from five young (20-24 years of age, mean 22.2 
years) and five old donors (62-82 years of age, mean 74.6 years) (see Table 
4 for details). BM-MSCs were cultured until senescence was reached and 
samples for further analysis were collected from every other passage. The 
proliferation capacity of young and old donors was similar, but considerably 
more interindividual variation was seen in the old donors group (Figure 11A 
and Publication I, Fig. 1). 
Replicative senescence was studied from selected cells and samples. We 
used morphology, telomere lengths, and protein expression of cell cycle 
components as indicators for replicative senescence. Late passage BM-MSCs 
gradually adopted the typical flattened morphology accompanied by 
increased cell size. Telomere length measurements showed that in passage 11 
cells telomeres were 1.0±0.5 kbp shorter than in passage 4 cells (Figure 
11B).  
The expression of cell cycle components p16INK4A and p21CIP/WAF1 were 
also increased in passage 11 cells in comparison to passage 4 cells as analyzed 
by western blot (Figure 11C). These results indicate that among the three 
selected cell donors, the degree of senescence and the proportion of 
senescent cells were not equally high.  
The immunosuppressive capacity of early and late passage cells was 
measured using CFSE staining and anti CD3 stimulated PBMCs. The early 
passage cells suppressed T-cell proliferation almost completely, but later 
passage cells were less immunosuppressive (Publication I, Fig. 1). 
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Figure 11 Proliferation and senescence of BM-MSCs. A. Cumulative population doublings at 
the end of the cell culture. The proliferation capacity between young (n=5) and old donors (n=5) 
is similar, but there is more individual variation among the old donors group. Non-parametric 
Mann-Whitney test was used to test the difference between groups (ns= non significant) B. 
Telomere lengths (TRF, Terminal restriction factor) were determined in early and late passage 
cells. Results are mean+SD of three BM-MSC donors. Paired one-tailed t-test was used to test 
the difference between the means. * P<0.05. C. Representative result of western blot analysis of 
cell cycle components p16 and p21. β-actin was used as a loading control. 
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5.2.1 MSC lipid profile changes during in vitro expansion 
Prior to use in therapy, MSCs need to be extensively expanded. While the 
effect of expansion on the DNA integrity, miRNA profiles, and gene 
expression has been previously studied, other molecular level changes are 
less well-studied. We had very little knowledge about membrane GPL 
composition of MSCs, along with the kind of changes that might take place in 
membrane composition during expansion. We used lipidomic approach to 
analyze cellular GPLs and total FA profiles from young and old donors. GPLs 
were analyzed with ESI-MS/MS techniques and the FA composition of total 
lipids was measured with gas chromatography. All results are shown as mol 
% per total lipids in that class or per total FAs. 
The GPL class profiles demonstrated that PC and 
phosphatidylethanolamines (PE) are the most abundant types of 
phospholipids in MSCs. This result is in line with other reports, apart from 
the MSCs having a higher proportion of PE than the previously described, 
otherwise very similar, fibroblasts (Blom et al. 2001)(Publication I, Table 1). 
When young and old donors were compared, the GPL profiles were highly 
similar. 
During expansion, phosphatidylinositol (PI) totals increased. This 
phenomenon was more evident when PI totals were compared to 
phosphatidylserine (PS) totals. The increase of PI was more evident in the 
BM-MSCs from young donors, since in the BM-MSCs from old donors the 
PI/PS ratio was already high in the early passage cells (Publication I, Fig. 3). 
Expansion of BM-MSCs induced alterations in the mol percentages of 
numerous phospholipid species especially in the PC and PE classes-. In 
general, long and unsaturated PL species were increased at the expense of 
shorter and monounsaturated species. The molar percentage of PC38:4, 
PC36:4, PC36:1, PE38:4, PE38:1, and PE36:4 increased towards late 
passages while PC34:1, PC34:2, PE36:1, and PE34:1 decreased. Most 
noticeable increase was observed in PC38:4 and PE38:4, which happened at 
the expense of the monounsaturated species PC34:1 and PE36:1 (Figure 
12). 
The FA profiles measured by GC supported the clearest finding in PC and 
PE phospholipid species. The increases in PC38:4 and PE38:4 were 
accompanied by a clear increase in 20:4n-6 in FA profiles. At the same time, 
the two most prominent n-3 PUFAs, 22:5n-3 and 22:6n-3, decreased, the 
effect being clearer for 22:6n-3 (Figure 13). In addition to measuring the 
relative quantities of different FAs in the BM-MSCs and FBS, we also 
measured the total quantity of FAs available for BM-MSCs on the culture 
dish. These results demonstrated that there is an excessive quantity of 
essential FAs for cells. (Publication I, Fig. 5B). 
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Figure 12 Effect of expansion on selected PC and PE species in hBM-MSCs. Mean values 
of PC38:4, PC34:1, PE 38:4, and PE 36:1 over different cell passages (x-axis). Error bar 
represents SD of individual BM donors, n=5 
 
Figure 13 Effect of expansion on selected PUFAs and threis ratios in hBM-MSCs. Results 
are mean+SD of all donors. (n=10). For FBS, three replicates were analysed. 
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5.2.2 Gene expression changes related to donor age and cell 
expansion 
In order to elucidate the role of gene exression regulation during expansion, 
we analysed mRNA expression and miRNA expression in passage 4 and 
passage 8 cells. Previous findings on proliferation kinetics and lipidomic 
changes had shown that most dramatic changes occur at passage 8. 
Therefore, p8 was selected as the late passage time point for microarray 
experiments. Gene expression analysis demonstrated that mRNA expression 
was remarkably different already in the early passage BM-MSCs of young 
and old donors (Publication I, Fig. 6). MiRNA expression, on the other hand, 
was very robust, and only minor changes between young and old donors were 
observed (data not shown). Expansion seems to have a different effect on the 
BM-MSCs from young and old donors. The expression of only 36 mRNAs 
and 12 miRNAs was changed during the expansion in both young and old 
donors’ BM-MSCs. Thus, the majority of the observed differences were 
unique to either the young or old donors (Publication I, Fig. 6; Publication II, 
Fig. 1). 
We selected five common miRNAs for qPCR validation. The qPCR results 
confirmed our microarray results, and we also showed that while miRNA 
expression mostly increases gradually, it takes a leap from passage p6 to p8 
(Table 5, Publication II, Table 1 and Fig. 2). BM-MSCs were passaged when 
confluency was 80%, resulting in different culture times. At p8, the culture 
time varied between 31 and 71 days. We noticed that miRNA expression 
levels measured as dct values showed similar variation. We performed a 
correlation analysis, whichshowed that miRNA expression correlates 
significantly with the expansion time (at passage 8) (Table 5). 
Table 5. miRNA expression and correlation analysis between 
miRNA expression and expansion time. BMMSC donors 081 
and 271 were removed from FC calculations. Correlation of dct 
values at passage 8 with expansion tile (days) was calculated 
using spearman’s correlation (n=9). 
miRNA FC p r p 
miR-1207-5p 1.3 0.004 -0.8 0.007 
miR-1915-3p 2.5 <0.001 -0.8 0.01 
miR-3665 2.6 0.002 -0.5 0.07 
miR-4281 1.42 0.004 -0.7 0.02 
miR-762 2.13 0.006 -0.7 0.02 
 
Detailed analysis of differentially expressed genes revealed that the 
expression of several genes operating in lipid metabolism were decreased in 
the old donors’ cells already at passage 4. These genes included FA 
desaturases FADS1, FADS2, SCD, lysoPC acyltransferase genes LPCAT2 and 
LPCAT3, FA elongase 3 (ELOVL3), and leukotriene C4 synthase (LTC4S). In 
addition, the PTGS1 gene coding cyclooxygenase 1 enzyme (COX1), which is 
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responsible for PGE2 synthesis, were more highly expressed in passage 8 
cells (old donors) than in passage 4 cells (Publication I, Table 3). 
As an indicator for the modulation of immune functions, the genes for the 
suppressors of cytokine signaling (SOCS1 and SOCS3) were expressed at a 
lower level in the old donor cells (at passage 4). In addition, the expression of 
SOCS3 decreased during passaging in the old donors group. Interestingly, 
SOCS3 is a predicted target for three miRNAs (miR-181-5p, miR-762, and 
miR-2861) whose expression increased during expansion (Publication I, 
Table3, Publication II, and Fig. 2). 
A more detailed analysis of miRNA changes demonstrated that the 
expression of miRNA cluster 17/92 was decreased either in old donors’ cells 
(miR-17, miR-18a, miR-19a, and miR-20a) or in young donors’ cells (miR-93, 
miR-25, and miR-92a-3p) (Figure 14). This cluster has been studied 
extensively, with the results indicating downregulation of miR-17, miR-20a 
and miR-106a in aging (Hackl et al. 2010). MiRNAs are found as clusters in 
the chromosomes, with miRNAs belonging to the same cluster most likely 
expressed together. In addition, miRNA in miR17/92 cluster and its 
paralogues miR106a/363 and miR106b/25) are divided into four families 
according to their seed sequences (see Figure 14). MiRNAs with similar 
seed sequences are likely to target the same genes and to share similar 
functions. 
 
 
 
Figure 14 miR17/92 cluster. Differential expression in BM-MSCs of members of the miR-17/92 
cluster and its two paralogues miR-106a/363 and miR-106b/25 and their differential expression in 
BM-MSCs during expansion. o8-o4 old donors group, y8-y4 young donors group, c8-c4 common 
group. Purple: members of the miR-17 family; blue members of the miR-18 family; green 
members of the miR-19 family; orange; member of miR-92 family 
 
miR-17 miR-19a miR-18a miR-20a miR-19b-1 miR-92a-1 
miR-106a miR-20b miR-18b miR-19b-2 miR-92a-2 miR-363 
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 57 
6 DISCUSSION 
Cells are extremely complex, yet organized entities. In a single cell, there are 
myriad of genes, protein, and lipids, which are all strictly regulated in order 
to allow the cells to fulfill their tasks and functions. The development of new 
technologies and bioinformatic tools has led to an era of “omics”, a field 
where the numerous molecules of a cell are examined as an entity.  This 
approach presents certain challenges: How to comprehend the massive data? 
How the relevant information is filtered from the irrelevant? What do these 
results mean in a context of cell biology? In this study, one of the challenges 
was to utilize omics data and to convert it to applicable information about 
MSCs functionality. 
MSCs contribute to the maintenance of the hematopoietic niche in the 
bone marrow and placenta. They are rare in the body, and therefore 
extensive in vitro passaging is required before use in therapeutic 
applications. MSCs, like all other primary cells, do not divide infinitely, but 
their proliferative capacity is limited. The effects of expansion on MSCs’ 
molecular composition and functionality are poorly understood. Donor age is 
one factor that is associated with a loss of proliferative capacity and cellular 
senescence of MSCs. Biological markers for cellular senescence indicate that 
MSCs from old donors show accelerated senescence (Stenderup et al. 2003). 
In the field of advanced cell therapy, the use of autologous MSCs also for 
older patients is continuously increasing. 
The aim of this study was to investigate the effects of donor age and 
extensive expansion on the proliferation, quality, and immunosuppressive 
capacity of hBM-MSCs. We used the omic approach to analyze the molecular 
changes in hBM-MSCs during extensive expansion. 
6.1 Lipid metabolism is connected to MSCs 
functionality  
In this study, we analyzed the membrane GPL and cellular FA composition of 
hBM-MSCs. In general, we showed that the GPL composition of membranes 
is highly similar to that previously reported for fibroblasts: only the PE level 
is higher in MSCs than in fibroblasts, which in other respects are very similar 
to MSCs. Next, we studied how expansion changes the GPL species 
composition of hBM-MSCs. We observed that the proportion of 20:4n-6 
containing PC and PE species (38:4 and 36:4) increased, whereas n-3 PUFA 
containing species (40:5, 40:6 and 40:7) and shorter monounsaturated 
species decreased. These findings were supported by FA analysis. Aging 
MSCs accumulated 20:4n-6 and lost 22:6n-3 and other n-3 PUFAs. The 
20:4n-6 is a precursor for several pro-and anti-inflammatory lipid 
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mediators, such as prostaglandins and lipoxins (Figure 15) (Stables and 
Gilroy 2011).  
The shift in the balance between n-6 and n-3 PUFAs may influence 
responsiveness to inflammatory signals and capability for 
immunomodulation (Schoeniger et al. 2011). This hypothesis was 
strengthened by the observation that both expansion and a high content of 
20:4n-6 resulted in decreased capacity for T-cell proliferation. In addition, 
our gene expression data revealed that the expression of COX-1 gene PTGS1 
was elevated in late passage cells compared to early passage cells. A similar 
pattern was seen in the PTGS2 gene, but the difference was not statistically 
significant. 
A simultaneous decrease in the n-3 PUFA content is of immunological 
importance as well. Traditional eicosanoids have been found to be 
accompanied by SPMs, including resolvins, protectins, and maresins, which 
are derivatives of 22:6n-3 and 20:5n-3 FAs. SPMs are needed in the 
resolution phase of inflammation (Serhan et al. 2015, Stables and Gilroy 
2011). SPMs, which are mainly produced by macrophages and neutrophils, 
prevent inflammation from spreading and halt the formation of chronic 
inflammation. SPMs are described as modulators of innate immunity but 
little is known about their effects on the cellular components of adaptive 
immunity. Both CD4+ and CD8+ T cell responses are reduced by RvD1, 
RvD2, and Mar1. Particularly the differentiation of Th17 cells was inhibited 
(Chiurchiu et al. 2016). Even though MSCs have several properties that 
suggest a potential role also in the resolution phase of inflammation, little 
evidence of the secretion of SPMs is available. Human periodontal stem cells 
with MSC-like characteristics have been shown to produce several 20:4n-6, 
20:5n-3, and 22:6n-3-derived mediators, but their role in MSC mediated 
immune modulation remains to be elucidated (Cianci et al. 2016).  
It is important to highlight that same cyclooxygenase and lipoxygenase 
pathways produce different lipid mediators with completely different, even 
opposing, functions (Figure 15). Different GPL/FA compositions in the cell 
may cause hBM-MSCs to respond very differently to the same external 
stimuli. The availability of GPL/FA substrate is reflected also in the produced 
lipid mediators and ultimately in the functionality of MSCs. 
In this study, MSCs were cultured in FBS. Due to the constant excess 
quantity of FAs in the surrounding medium compared to the cells, we can 
assume that the observed changes in hBM-MSC lipidome were due to an 
active senescence-associated process. However, it is possible that 
supplementing the culture medium with even more n-3 PUFAs might 
support hBM-MSCs growth and maintain their physiological functionality. 
Interestingly, our group has shown that MSCs are not able to synthesize long 
chain PUFAs from the short chain precursors (18:2n-6 or 18:3n-3). Thus, 
22:6n-3 should be added to culture medium in order to increase 22:6n-3 
levels in MSCs (Tigistu-Sahle et al. 2017). However, there may be a limit as 
too high n-3 PUFA contents in membranes may even impair raft-related 
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functions and signaling events occurring in lipid rafts (Fan et al. 2004, Turk 
and Chapkin 2013). 
In therapeutic applications, FBS is more often replaced by human platelet 
lysate or other animal-free supplements. These products show more 
variation between batches, which may be caused by differences in growth 
factor concentrations, but the FA composition of these products may also 
vary. It would be interesting to compare the lipid profile and its changes 
during passaging in xeno-free cultured MSCs and compare the results with 
MSCs cultured in FBS. 
 
Figure 15 Scheme of n-6 and n3 PUFA metabolism and release of lipid mediators. Green 
and red arrows indicate either increase or decrease, respectively of FA or mRNA levels observed 
in this study. p4-p8 refers to change during expansion and o4-y4 refers to difference between 
young and old donors at passage 4. Abbreviations: AA, arachidonic acid; COX cyclooxygenase; 
DHA, Docosahexaenoic acid, ELOVL, fatty acid elongase; EPA eicosapentaenoic acid; FADS 
fatty acid desaturase, LOX lipoxygenase, LT, leukotriene; MaR, maresin; PG, prostaglandin; 
PUFA, polyunsaturated fatty acid; Rv, resolvin; TX, thromboxane.  
6.2 MicroRNA regulation connects cell cycle and 
immunoregulation  
In the second publication in the thesis, we further investigated expansion-
induced changes in hBM-MSCs. We noticed that miRNA levels were 
relatively robust during expansion. In this study, the most highly expressed 
miRNAs were generally the same that have previously been described and 
reviewed by Clark et al. (2014). This indicates that MSCs have a particular 
miRNA expression pattern that is not susceptible to changes. 
In this study, we had the opportunity to investigate the possible miRNA-
mRNA interactions and their role in the proliferation of MSCs. We used a 
microarray platform to analyze miRNA and mRNA expression in the same 
cells. We used an ingenuity pathway analysis tool to predict potential targets 
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for miRNAs and then combined this information with the actual expression 
levels in the cells. As expected, we saw that in many cases the expression of 
miRNA and its potential target changed in opposite directions (Publication 
II, Fig.4). However, in many cases the expression of miRNA and its target 
mRNA changed in same direction. There are several possible explanations 
for this. The most likely one is that our experiment did not catch the direct 
and short-lived causality of the miRNA and its target mRNA. Also, the 
expression of miRNA and its target may be regulated by the same factor or 
mechanism. Further, as miRNA regulation is post-trancriptional, it is not 
self-explanatory that miRNA regulation is seen automatically as reduced 
expression of its target mRNA. And again, miRNAs regulate tens to 
thousands of mRNA molecules. Development of prediction tools offers an 
excellent starting point for narrowing down the potential targets or signaling 
routes, but further experimental validation is needed to fully understand the 
role of spesific miRNAs in MSCs functionality. 
MiRNAs are involved in many cellular processes, and especially in the 
development and differentiation of stem cells. In the context of MSCs 
biology, several miRNAs have been shown to regulate the differentiation, 
proliferation, and immunosuppression of MSCs. Our analysis revealed that 
several members of the miR17/92 cluster were down-regulated in old donor 
cells and in a few members of the young donors group. This miRNA cluster is 
of a particular interest since miR-17, miR-20a, and miR-106a are down-
regulated in aging (Hackl et al. 2010). It is also known that the cell cycle 
regulator p21, whose expression is increased in senescent cells, is regulated 
by this cluster (Gomez-Cabello et al. 2013, Ivanovska et al. 2008). 
6.3 Extracellular vesicles mediate immunoregulative 
functions of MSCs  
The therapeutic effect of MSCs is currently explained by their capacity to 
regulate immune cells through paracrine mechanisms. MSCs secrete EVs 
that are immunosuppressive (Di Trapani et al. 2016) and repair injured 
tissues in ischemic animal models (Bruno et al. 2009, Collino et al. 2015, He 
et al. 2012). Although the effects of external cytokine stimulus in the MSC-
mediated immunosuppressive mechanisms have been widely studied, the 
effect on EV production is less well-known. In this study, we show that hCB-
MSCs secrete constitutively (in serum deprivated culture media) EVs that 
remarkably attenuate IRI in a rat model. Our results are thus in line with 
previous reports demonstrating that BM-MSC-derived EVs are 
renoprotective in the early phase of AKI. Innate immunity plays a major role 
in regulating the early phase of AKI. MSCs are known to interact with innate 
immune cells regulating, for instance, the macrophage polarization toward 
an anti-inflammatory M2 phenotype. Recently, the role of MSC-derived EVs 
in macrophage polarization was also demonstrated (Lo Sicco 2017).  In 
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literature, the IFNγ concentration used to stimulate MSCs ranges from a few 
ng/ml up to 100 ng/ml. In this study, we used the highest concentration, 100 
ng/ml, to stimulate CB-MSCs to produce EVs. We noticed that whenMSCs 
were stimulated with a high quantity of IFNγ, the protective effect of EVs was 
not seen.   
The proteomics analysis of stimulated and non-stimulated CB-MSC EVs 
showed clear differences between these two groups. In stimulated CB-MSC 
EVs, the presence of MHC I was observed, which at least partly may explain 
why they were not protective in the AKI model. Therefore, it is highly 
possible that innate immune cells recognize these EVs as foreign and 
consequently they are lysed. Further, we identified larger number of proteins 
from stimulated EVs compared to non-stimulated EVs. The further analysis 
of individual proteins gave us some candidates that could explain the 
differences observed in the functionality of EVs. Strikingly, our proteomic 
data imply that IFNγ stimulation induces EV production via a secretory 
route, whereas constitutively produced EVs were produced by either 
membrane blebbing or by rapid recycling route. This could explain the 
observed differences in protein content, such as exosomal markers that were 
found only from stimulated EVs. EVs also contain other molecules in 
addition to proteins, such as lipids, miRNAs, and mRNAs, whose role in EV-
mediated immunosuppression requires further studies. 
 
6.4 Conclusions and future perspectives 
In this study, we provide new insight into the importance of the membrane 
lipid composition and lipid metabolism for the functionality of MSCs. We 
show for the first time that major changes take place in the composition of 
GPL species and total FAs during expansion of therapeutically important 
hBM-MSCs. We demonstrate that the cellular relative content of 20:4n-6 
increases while that of n-3 PUFAs decrease. The PUFA alterations reported 
here presumably affect the production of pro- or anti-inflammatory 
eicosanoids, as well as SPMs needed for resolution of inflammation. Thus, 
our results will serve as a basis for further studies aimed at understanding 
the role of lipid mediators in MSC-mediated immunosuppression. 
Modification of culture conditions may serve as one way of preventing the 
harmful effects of long-term cell culture. On the other hand, we show that the 
immunosuppressive capacity of BM-MSCs shows variation that correlates 
with the PUFA composition of the cells. Therefore, selected lipid or FA 
molecules may serve as biomarkers for the good quality and functionality of 
MSCs. 
In addition to changes in lipid molecules, we investigated gene expression 
changes in hBM-MSCs. We demonstrated that gene expression of MSCs from 
young and old donors differed already at passage 4, but the expansion 
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induced changes were minor. In general, the changes observed in both 
miRNA and mRNA expression levels were moderate. This may be because 
MSCs are an extremely heterogenous cell population and a given cell culture 
probably contains many different types of MSCs. Gene expression of single 
cells should be studied using single cell analytics to gain a more profound 
understanding of different populations and their characteristics in this 
heterogeneous pool of MSCs. This new analytics method will most likely help 
us to understand the puzzling question of whether all MSCs are equally 
multipotent or whether we need to admit that MSCs are actually a collection 
of cells with different abilities 
We further investigated the role of miRNA regulation of BM-MSCs. 
MiRNAs have been shown to have a role in many aspects of MSC biology. In 
this study, we report comparative analysis of miRNA expression in young 
and old donors at the early and late passages. We demonstrate the regulative 
network that connects the regulation of the cell cycle and immune regulation. 
This observation needs further validation. We also report that MSCs secrete 
EVs that are immunosuppressive in vitro and protect against acute kidney 
injury in vivo. In this study, we used CB-MSCs instead of BM-MSCs since 
they seemed to be more active in producing EVs, critical study material for 
many different experimental steps.  Research should next be extended to 
BM-MSCs, since BM is still the most frequently used MSC source in cell 
therapy. In future experiments, the mRNA and miRNA content of EVs 
should be investigated. Since EVs are membranous structures it is plausible 
that they transport also lipid mediators, or enzymes that may catalyze the 
production of these mediators from the lipids of EVs in situ. Whether the 
lipid composition of EVs resembles the cell membrane of the mother MSCs 
and what role EVs play in the immunosuppression of MSCs are questions 
that require further investigations. 
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